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PREFACE

This dissertation is written based on three papers which have been published in different
journals. Chapter two is partially based on a review article that was published in the Journal of
RSC Advances: “Elyahb A. Kwizera, E. Chaffin, Y. Wang, X. Huang, Synthesis, and Properties
of Magnetic-Optical Core-Shell Nanoparticles. RCS Advance 2017,7, 17137-17153.”
Chapter three is based on an article that was published in the Journal of Physical Chemistry C:
“Kwizera, E. A.; Chaffin, E.; Shen, X.; Chen, J.; Zou, Q.; Wu, Z.; Gai, Z.; Bhana, S.; O’Connor,
R. T.; Wang, L.; Adhikari, H.; Mishra, S.; Wang, Y.; Huang, X. Size-and Shape-Controlled
Synthesis and Properties of Magnetic-Plasmonic Core-Shell Nanoparticles. J. Phys. Chem. C
2016, 120, 10530-10546.”
Chapter four is based on an article that was published in Journal of Theranostics: “Elyahb. A.
Kwizera, R. O’Connor, V. Vinduška, M. Williams, Y. Wang, X. Huang. Detection and
Molecular Profiling of Exosomes Using Surface-Enhanced Raman Scattering Small Gold
Nanorod and Miniaturized Device. Theranostics 2018; 8(10):2722-2738.” In these chapters, all
tables, figures, schematics and references have been reformatted and renumbered to fit into one
document. The references and style used within this dissertation reflect the standards of Royal
Society of Chemistry Advances
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ABSTRACT

Kwizera Elyahb Ph.D. The University of Memphis. August 2019. Multifunctional
nanomaterials for blood-based cancer detection. Major Professor: Xiaohua Huang. Ph.D.

Multifunctional nanomaterials have emerged as unique nanoplatform with excellent
physical and physiochemical properties such as their facile surface chemistry, excellent
biocompatibility and remarkable optical properties which allow them to be used for early cancer
detection, biological separation, medical imaging, disease detection, and disease treatment.
However, due to their small sizes, their size distribution, surface chemistry and their complex
morphology, there is a significant challenge in their synthesis and their characterization. Therefore,
a thorough understanding of their structure with a detailed physiochemical characterization and
their functional properties is highly essential. In this dissertation, we summarize a tremendous
progress that has been made in the last few decades in synthesizing and characterizing magneticplasmonic core-shell nanoparticles, mainly iron oxide-gold core-shell nanoparticles. We report
different approaches for the synthesis of spherical and anisotropic magnetic plasmonic core-shell
nanoparticles focusing on iron-oxide gold core-shell nanoparticles. Growth mechanisms are
discussed in detail to provide an understanding of the key factors that play a big role in shape and
size of nanoparticles. We have developed iron oxide gold core shell nanoparticles in different
shapes (sphere, popcorn and star) with controllable sizes (70 to 250 nm). The nanoparticles were
synthesized via a seed-mediated growth method in which newly formed gold atoms were added
onto gold-seeded iron oxide octahedrons to form a gold shell. With their strong magnetic
properties, these nanoparticles allow faster biological separation and can be used for medical
imaging and will have a very important impact in many different fields including cancer detection
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and therapy. We have also investigated the use of multifunctional nanomaterials in the detection
of cancer derived exosomes and protein profiling. We have developed portable, highly sensitive,
and highly specific assay based on surface enhanced Raman scattering gold nanorods and
antibody-capture platform on a multi well capture device. This assay is very sensitive with a limit
of detection of 2x106 exosomes/mL and can analyze more than 80 samples on a single device
within two hours. Through proof of concept studies, we identified HER2 and EpCAM to be breast
cancer derived exosome biomarkers which suggest that they can be used as diagnostic tools for
breast cancer.
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Chapter 1. INTRODUCTION
1.1.

Cancer Diagnostics
Like many human diseases, cancer is a preventable disease. Numerous studies have

shown that more than 20% of all cancers can be avoided or prevented by reducing personal
weight1, increasing physical activities2, stopping cigarette smoke,3-5 limiting alcohol
consumption6-8 and increasing healthy diet intake.3, 9-11 It can also be prevented by avoiding or
reducing environmental and carcinogenic substance exposure.12-17 However, despite all
mentioned preventative measures, there is a still high number of cancer patients with National
Cancer Institute projecting that in 2019, close to 1,762,450 people will be diagnosed with the
disease in United States alone with more than 606,880 people projected to die from it.18
Therefore, an identification of cancer at an early stage could potentially lead to significant
decreases in morbidity and mortality, therefore contributing to saving lives worldwide.
Numerous tools for cancer diagnostics have been developed and the development of
minimally invasive tests for cancer detection, progression and monitoring are being improved
day by day to find an efficient, cost-effective and more sensitive ways for cancer detection. For
cancer to be effectively defeated, it is highly crucial to get an early diagnosis. Conventional
detection tools such as chest X-ray, radiographic screening, mammography, and other different
types of invasive biopsies rely heavily on nonspecific traditional screening methods that lack the
superior sensitivity and specificity.19-21 This leads to many false-positive and false-negative
diagnoses, as well as overdiagnosis which is a big concern in oncology.
The fact that some types of cancer including brain and lung are located in remote area
makes it almost impossible to routinely monitor their progress, therefore they require invasive
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biopsies which can cause potential harm to patient health.20, 22-24 Recently, there has been an
urgent need to develop new effective and less invasive cancer detection techniques that allows
molecular tests with superior sensitivity and specificity capable of detecting cancer at its earliest
stages. Recent approaches have shown that blood-based biomarkers combined with
multifunctional plasmonic or magnetic nanomaterials are clinically promising cancer detection
tools that will improve cancer diagnosis.25-29 Multifunctional nanomaterials in combination with
blood-based biomarkers are very appealing due to their minimal toxicity and their
biocompatibility. They are anticipated to revolutionize the cancer diagnosis and therapy.25, 28-35
However, the development of clinically validated cancer detection tools remains a big challenge
especially due to the complexity and heterogeneity of different types of cancers and the
complicated synthesis of nanomaterials that are well tuned for cancer detection.35-41 As a result,
significant progresses have only been made in the last few decades.
1.2. Blood based Biomarkers

Due to the limitation in tissue biopsy,20, 22-24 blood-based biomarkers have been found to
have a critical potential in cancer diagnosis, screening and therapy.42-44 They may be produced
by cancer cells themselves, they could be generated by the host in response to the cancer attack
or by the tumor microenvironment.15, 45, 46 These biomarkers pave a path to the use of noninvasive liquid biopsy which is accessible to large populations, very inexpensive, and allows for
repeated testing for real-time monitoring of disease stage and treatment response.45 Tumorderived biomarkers in a biological fluid sample rather than a tissue sample may be sampled from
different biological fluids such as urine,47 whole blood,48-51 serum,44, 50 plasma,52-54 saliva,55
cerebrospinal fluid,56 bronchial sputum.51, 57, 58 Blood based biomarkers can be divided into

2

circulating vesicles, circulating tumor cells, circulating proteins and circulating nucleic acids
categories. A great deal of work has been accomplished in each category to detect cancer at
earliest stages, but each work has faced numerous challenges. One of the biggest challenges is
that biological markers are found in multicomplex environment. For instance, cancer derived
circulating vesicles such as exosomes which are under scientific spotlight as potential cancer
biomarkers are shed by cells into an extracellular environment which is dominated with lipids,
proteins, microvesicles and exosomes from normal cells. Therefore, the detection and analysis
require a very sensitive and highly specific technique to probe cancer-derived exosomes in
presence of all other biomolecules. The use of multifunctional nanomaterial to overcome all
these issues have proved exceptional as they exhibit exceptional functional and optical properties
that are often not available from either bulk materials or other discrete molecules.33 With their
large surface-to-volume ratio, nanomaterials are excellent for highly efficient target interactions
with biological markers, they are able to provide superior sensitivity and be able to probe the
cancer marker despite the multicomplex environment. These properties can also be exploited to
enhance the performance of existing detection methods or develop new assays with
ultrasensitivity and multiparametric capabilities.59-62
1.3.

Gold Based Nanoparticles
Among the known multifunctional nanoparticles, gold nanoparticles (Au NPs), iron oxide

gold core shell nanoparticles (IOAu NPs) and Quantum dots nanoparticles (QD NPs) are the
most common (Figure 1.1). For instance, gold nanoparticles (Au NPs) are very unique for
biomarker detection due to the fact that they are very easy to synthesize, they have a facile
chemistry, they are biocompatible, and their special optical properties allow them to be tuned
from visible to near infrared (NIR) region where most of biological applications are optically
3

active.63 These special properties make them very attractive and have been the origin of many
increasing efforts to even learn more ways to make different types of gold nanoparticles in terms
of shapes and sizes. Just like most noble metal nanoparticles, gold nanoparticles exhibit a s very
strong Localized Surface Plasmon Resonance (LSPR) which is an attractive characteristic of
metal nanoparticles which involve the collective oscillation of conduction band of electrons in
metal nanoparticles that are excited by the electromagnetic field of incident light.64 This LSPR is
highly dependent on other surrounding nanoparticles, shapes and sizes of nanoparticles,
aggregation state and variation in interparticle spacing.65 With this strong LSPR, gold
nanoparticles express a fluorescence and absorbance that is higher compared to that its bulk gold
solution.66 Their strong scattering and absorption properties can reach the extinction coefficient
maximum of 108 up to 1011 M-1cm-1 depending on their shapes, sizes or structures.67, 68
Additionally, molecules that are adsorbed on the surface of these noble nanomaterials undergo a
very strong chemical, magnetic and field enhancement which are very important for the surface
enhanced raman scattering (SERS). For instance, an increase of strong Raman signal of
adsorbed molecules has been reported to reach an enhancement factor of 1014-1015 when
hemoglobin molecules were adsorbed on silver nanoparticles that are immobilized on the
polymer-coated silicon wafer.69 This have been confirmed again by Nie and Emory when they
adsorbed Rhodamine-6G molecules on silver colloids that have been immobilized on polylysinecoated glass surface.70 The combination has an ultrasensitive capability to detect a single
molecule despite the background environment of a target molecule. Therefore, multifunctional
nanomaterials are the best tool for cancer diagnostics, especially with their ability to detect low
concentration of cancer marker in multicomplex environment or their ability to have a
modifiable surface which is critical in cancer diagnostics.
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Figure 1.1. Three most common multifunctional nanomaterials include gold nanoparticles,
magnetic nanoparticle and quantum dots nanoparticles

With these excellent and unique optical properties, gold nanoparticles have become the
holy grail for scientist around the globe for their use in development of ultrasensitive platforms
for biomarker detection, photothermal therapy and drug carrier due to their unique surface
plasmon resonance property (Figure 1.2). They can be used alone or used as a shell layer to a
magnetic core nanoparticle for different types of biological functions. They can be easily
functionalized with a biomolecule such as antigen, drugs or an organic polymer. For examples,
Bhana et al have developed a system for combined photothermal therapy (PTT) and
chemotherapy using NIR-absorbing gold nanorods (AuNRs) carrying chemotherapeutic
paclitaxel (PTX). The drug was entrapped with high density in the hydrophobic pocket of
polyethylene glycol (PEG) monolayer on the surface of AuNR. This system was able to deliver
drugs into the lipophilic layer of plasma membrane.71 Gold nanoparticles also can act as near
infrared imaging probes on their own for cancer detection due to their unique optical properties.
Sokolov et al have conjugated AuNPs with antibody against epidermal growth factor receptor
(EGFR) and used them to detect cancer cells using a scanning confocal microscope in the
reflectance mode with a 647 nm laser to excite the SPR of AuNPs. They found that cells with
gold nanoparticles conjugates were clearly imaged than those that didn’t have Au NPs on them.72
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This provide an excellent imaging tool for cancer biomarkers because imaging ability of current
tools such as optical microscopes is limited in terms of resolution and detection limit.
Jokerst et al have successfully used AuNRs with aspect ratio of 3.5 to image
subcutaneous xenografts of the SKOV3, HEY and 2008 ovarian cancer cell lines in living mice.
Their system combined photoacoustic imaging and SERS imaging into a single multimodal
imaging agent using AuNRs. Using this system, tumor margins were Cleary visualized optically
with SERS modality and validated with inductively coupled plasma spectrometry. The Au NR
was stable with minimal toxicity in cell culture and had a detection limit of 17 fM which is better
than photoacoustic imaging previously reported of 50 nM obtained using carbon nanotubes and
50 pM gold nanospheres therefore, this technique offers more than 10 times improvement in
SERS signal compared to other alternative approaches.73

Photothermal Therapy

h𝝊

AuNPs
Targeting

Drug Delivery

Figure 1.2. Different applications of gold nanoparticles in cancer diagnosis, detection and
therapy. Multifunctional nanoparticles are utilized in different applications such as: Optical
imaging, targeting, drug delivery, photothermal therapy, ultrasensitive detection, nucleic acid
delivery and protein targeting.
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Multifunctional nanomaterials can also be combined or modified to develop a superior
material with a dual function. Nassirelslami and Ajdarzade have developed spherical
superparamagnetic iron oxide nanoparticles and modified their surface with gold, then they
conjugated the surface with the Deoxyribonucleic acid (DNA) based MUC-1 aptamer to increase
the specificity of nanoparticle delivery into cancerous cells. MUC-1 is a single stranded DNA
based aptamer that is used as a targeting agent using different kinds of nanoparticles on broad
range of epithelial cancer cells. They reported finding higher uptake on the aptamer modified
nanoparticles than bare nanoparticles which lead to significant death of MCF-7 cells.74
Nanomaterials such as gold nanoparticles have also been used for circulating biomarker
detection. One case is of exosomes where Betzer et al developed a method for noninvasive in
vivo neuroimaging and tracking exosome that involves the use of glucose coated gold
nanoparticles labeling and computed tomography imaging without labeling of parent cells. They
found that glucose-coated Au NPs were uptaken into MSC-driven exosomes via an active energy
dependent mechanism and this improved exosome labeling which led to superior brain
accumulation and enhanced in vivo imaging.75
SERS nanoparticles are usually stabilized with an organic molecule such as methoxypolyethylene glycol thiol (m-PEG-SH) or 16-mercaptoundecanoic acid (MHDA). These
molecules are linked with a polyethylene glycol heterofunctional molecule for ligand
conjugation. Nanoparticles in general are utilized in different field for different purposes as they
have many applications due to their optical properties, their biocompatibility, their large surface
area which can be modified to cater different usages such as antigen targeting, imaging and
detection (Figure 1.2). With this multifunctional role, they are deemed to be excellent tools in
cancer diagnostics and therapy.

7

1.4.

Overview of Chapter Contents
In chapter two, we report on the progress that has been made during the last few decades

in synthesizing and characterizing magnetic-plasmonic core shell nanoparticle mainly iron
Oxide-gold core-shell nanoparticles. We introduce different approaches for the synthesis of
spherical and anisotropic magnetic-plasmonic core-shell nanoparticles focusing on iron oxidegold core-shell nanoparticles in terms of growth mechanism and we also discuss on what key
factors that play a role in shape and size-controlled synthesis. We also summarize computational
and experimental studies to better understand the magnetic and optical properties of Iron oxidegold core shell nanoparticles.
In chapter three, we have investigated the experimental and computational studies on the
synthesis and properties of IO-Au core-shell nanoparticles of three different shapes (sphere,
popcorn, and star) with controllable sizes (70 to 250 nm). We answer one of the most critical
question in multifunctional nanomaterial synthesis which is what drives the size and shape
change of nanoparticles and how can we control the optical properties and magnetic properties of
metallic nanoparticles. We report on the controlled growth of nanoparticles and we elucidate the
intimate roles of thermodynamic and kinetic parameters in the shape-controlled synthesis. We
use chemical synthesis and computational calculation to understand the optical properties and we
have observed a shift to longer wavelength and broadening of plasmonic bands when the base
size (inner spherical IO-Au core) was increased. the LSPR peaks of the nanopopcorns shift to
longer wavelengths and the bands become broader, owing to the anisotropic Au shell of the
nanopopcorns. The NSTs show multispectral feature, with distinct peaks depending on the size
and they exhibit most red-shifted plasmon resonance compared to the spheres and popcorns due
to the elongated tip structure of the stars.76
8

In chapter four, we investigate the use of plasmonic nanomaterials for blood-based
diagnostics namely gold nanorods for molecular detection and analysis of exosomes. These 30300 nm membrane-based vesicles have recently emerged as potential new class of cancer
biomarkers for clinical diagnosis and treatment monitoring. With the combination of surface
enhanced raman scattering properties of multifunctional gold nanorods and a multiwell capture
assay; 2.0 x 106 exosomes/mL were detected. This assay provides an ultrasensitive detection of
exosomes that are 500 times lower than exosome concentration in the plasma. It is also very
rapid and can be able to provide profiling data within 2 hours which is very important for
efficient and effectiveness which is of a great importance for clinical setting. Finally, chapter 5
gives a summary and conclusion from all work done in this dissertation. It provides information
on how current work can be improved and it gives recommendations for future work.
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Chapter 2: Synthesis and Properties of Magnetic-Optical Core Shell Nanoparticles
2.1.

Introduction

Multifunctional nanomaterials are a topic of considerable interest across several sciences,
engineering and biomedical disciplines. The basic rationale is that nanoscale materials, typically
1-100 nm, exhibit exceptional structural and functional properties that are not available in bulk
materials or discrete molecules. Two major classes of functional nanoplatforms have been
extensively studied and widely used in a variety of fields: plasmonic nanoparticles (NPs) and
magnetic NPs (MNPs). Plasmonic NPs are typically composed of noble metals, generally gold
(Au) and silver (Ag). They exhibit unique localized surface plasmon resonance (LSPR), the
collective oscillation of the conduction electrons of the NPs in resonance with the electric field
of the incident light.77-79 This LSPR leads to strongly enhanced radiative (e.g. absorption and
scattering) and nonradiative (e.g. photothermal and energy transfer) properties.80, 81 Compared to
Ag NPs, Au NPs are more stable under ambient conditions. Additionally, the LSPR of Au NPs
can be tuned from the visible to near infrared region (NIR) by adjusting the particle's size, shape
and structure.81-85 These intriguing optical properties have made Au NPs highly favorable for
sensing, optical imaging, photothermal cancer therapy, catalysis, and many other material and
biomedical applications.86-90
Magnetic nanoparticles are commonly made of magnetic elements such as iron (Fe) and
cobalt (Co). Their chemical compounds show alignment of their magnetic moment in the
presence of an external magnetic field and concentrate the external magnetic flux density.91 This
magnetic response causes the attraction of the MNPs in the direction of applied magnetic
gradient and makes the MNPs very useful for many applications including data storage,
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spintronics, molecular and cellular isolation, magnetic resonance imaging (MRI) and
hyperthermia treatment of cancer.92-95 The most common MNPs are iron oxide nanoparticles (IO
NPs) including magnetite (Fe3O4) or maghemite (γ-Fe2O3). These MNPs have advantages of
ease-of-preparation, biodegradability, excellent stability, and the tunability of magnetic
properties through changes in size and shape, making them the most attractive MNP platforms.
When the sizes of these MNPs are smaller than 30 nm, they are superparamagnetic, otherwise
they are ferromagnetic.96 Superparamagnetic NPs avoid the induced aggregation associated with
the residual magnetization of ferromagnetic NPs. MNPs can be spherical or anisotropic such as
rods, cubes and stars. Thus, they provide versatile structural platforms for generations of
different nanostructures.
However, each of these NP types displays distinct limitations. For example, plasmonic
NPs lack the ability to separate analytes, which is usually required for the analysis of rare
molecules and cells in a complex milieu. MNPs do not exhibit the properties needed for highly
sensitive optical imaging. Thus, hybrid NPs with combined magnetic and optical properties are
much more powerful and can be used in a broad range of applications such as magnetic
resonance imaging,97-103 optical imaging,102-104 biological separation,105-113 molecular-cellular
detection,109-116 and cancer treatment.99-101, 103, 107, 117-119 Additionally, these hybrid NPs offer new
modalities that neither plasmonic NPs nor MNPs exhibit. For example, Jin et al. have
demonstrated the use of IO-Au core-shell NPs for magnetomotive photoacoustic imaging.120 This
novel imaging mode shows remarkable contrast enhancement compared with photoacoustic
images obtained using solid Au NPs. Magnetic-plasmonic core-shell NPs can consist of any
magnetic core such as Fe, Co or their oxides and a plasmonic shell such as Au, Ag or platinum.
However, IO-Au core-shell NPs have become the primary platform because of their remarkable
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advantages. The IO NPs are stable and easy to synthesize, and the Au surface offers facile
surface modification, excellent stability, and biosafety. The optical properties of the IO-Au coreshell NPs can be precisely tuned by changing the core size, shell thickness as well as the core
and shell shapes. A key to the technological applications is the synthesis of high-quality IO-Au
core shell NPs with desirable magnetic and optical properties. During the past decade, intense
research has been directed to make both anisotropic nanomaterials such as gold nanorods and IOAu core-shell NPs with different sizes and thicknesses for blood-based cancer diagnosis.
Synthesizing anisotropic nanomaterials requires precise control of the thermodynamic and
kinetic parameters of the growth solution.
2.2.

Synthesis of spherical IO-Au core-shell NPs
Making spherical IO-Au core-shell NPs can be divided into two major categories: The

first one is the direct deposition method where atoms are directly deposited onto IO NPs via the
reduction of Au precursor in a growth solution containing IO NPs. In this method, the surface of
the IO NPs may be chemically modified to adsorb Au ions to facilitate Au shell formation. The
second method is indirect deposition where Au atoms are deposited onto Au-seeded IO NPs in
which Au seeds serve as nucleation sites to facilitate the growth of Au shell. This Au-seeded
growth method requires more steps than the direct deposition method, but it provides flexibility
in tuning the morphology of Au shell by fine control the kinetic and thermodynamic parameters
of the growth solution.
Direct deposition methods. When two materials have similar crystal lattices, one material can be
directly deposited onto the other to form a uniform shell via epitaxial growth. The spacings of
Au are around and within 3% of those of Fe3O4 or γ-Fe2O3 (Table 1). Thus, it is possible to make
IO-Au core-shell NPs via epitaxial growth of Au on bare IO NPs. Bare IO NPs can be readily
12

prepared by the coprecipitation of a ferric chloride (FeCl3) and ferrous chloride (FeCl2) mixture
in an alkaline medium. Au atoms are deposited onto IP NPs via reduction of chloroauric acid
(HAuCl4) by sodium citrate in the presence of IO NPs aqueous solution at boiling
temperature.108, 121, 122
Table 2.1. Standard Atomic Spacing for Fe3O4, γ-Fe2O3 and Au Along With their Respective hkl
Indexes from the crystal structure database
(hkl) index

Fe3O4 (Å)

γ -Fe2O3(Å)

Au(Å)

111

4.85

4.82

2.35

220

2.97

2.95

1.44

311

2.53

2.52

1.23

400

2.10

2.09

1.02

422

1.71

1.70

0.83

Alternatively, this reduction can also be performed at room temperature by using sodium
borohydride (NaBH4) under sonication.110 Sonication results in better particle monodispersity
and avoids the agglomeration associated with ionic interactions. Other reducing agents such as
glucose can also be used to reduce Au3+ ions to Au atoms.123 The thickness of the Au shell can
be tuned by simply varying the ratio of IO NPs to Au precursor solution. Although this method is
simple and rapid, it also produces self-nucleated Au NPs that must be removed from the IO-Au
core-shell NPs, possibly via magnetic separation.
To synthesize IO-Au core-shell NPs with uniform Au surface, one approach is to
iteratively deposit Au atoms onto IO NPs via repeated reduction of Au3+ by hydroxylamine
(NH2OH).103, 104, 109, 115, 124, 125 NH2OH is known to promote Au3+ surface catalyzed reduction.126
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Thus, Au atoms are deposited only on the surfaces of IO NPs rather than forming self-nucleated
Au NPs. This method was first reported by Lyon et al. in 2004.124 In their studies, γ -Fe2O3 or
oxidized Fe3O4 NPs were immersed in sodium citrate for 10 min to exchange adsorbed
hydroxide anions with citrate anions. Au atoms were deposited onto the IO NPs via the reduction
of HAuCl4 by NH2OH at room temperature. Five additions of HAuCl4 and NH2OH were
performed to achieve continuous Au shells on the IO NP surfaces. Characterization by
transmission electron microscopy (TEM) showed that Au atoms were initially deposited onto
specific sites of the IO core, which led to a jagged Au surface. Au atoms from the subsequent
reduction steps filled the empty sites on the IO surface, producing a continuous Au shell and,
thus, uniform IO-Au core-shell NPs. This process also explained why the size of the core-shell
NPs did not change between the first and fifth depositions having similar sizes of around 60 nm
in diameter following each step. It is interesting to note that they were not able to form an Au
shell on the freshly prepared Fe3O4 NPs and this mechanism is yet to be investigated. The unit
cell parameters for both Fe3O4 and γ-Fe2O3 based cubic settings are almost identical with a =
0.845 nm for γ-Fe2O3 and a = 0.840 for Fe3O4.127, 128 Therefore, the success of the Au shell
formation on Fe2O3 and oxidized Fe3O4 NPs but not on freshly prepared Fe3O4 NPs cannot be
ascribed to the lattice dissimilarity between the IO NPs and Au.
Au
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MNP

Repeated HAuCl4

HAuCl4

MNP

NH2OH

MNP

Repeated NH2OH
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Figure 2.1. Synthesis of IO-Au core-shell NPs by the direct deposition method. (A) Synthesis of
IO-Au core-shell NPs by iterative hydroxylamine seeding. Top: Schematic of the preparation
procedure. Bottom: TEM images of IO-Au core-shell NPs with zero, one, three, and five times of
deposition of Au atoms via reduction of Au3+ with hydroxylamine, respectively. Reprinted with
permission from ref. 125. Copyright (2009) American Chemical Society. (B) Synthesis of IO-Au
core-shell NPs by hydroxylamine reduction of Au precursor on the surface of polymer-coated IO
NPs. Left: Schematic of the preparation procedure. Right: TEM image of Fe3O4 NPs and Fe3O4Au core-shell NPs. Reprinted by permission from Macmillan Publishers Ltd: [Nature
Communications] (ref.120), copyright (2010).

Tamer et al. modified the method by treating the oxidized Fe3O4 NPs with
ethylenediaminetetraacetic acid (EDTA) before Au coating and reduced HAuCl4 with NH2OH in
the presence of EDTA-immobilized Fe3O4 NPs and cetyltrimethylammonium bromide (CTAB)
in a basic solution was added.110 Uniform, highly stable IO-Au core-shell NPs with a narrow size
distribution were produced with one-step reductive Au deposition. In a different study by Zhang
et al., Fe3O4 NPs were modified with 3-aminopropyltrimethoxysilane (APTMS) before reductive
deposition of Au with NH2OH.110, 129 APTMS modification was used to facilitate Au ion
adsorption because of its positive charge.
Another technique for forming IO-Au core-shell NPs is to perform the Au deposition in a
microemulsion130 or nanoemulsion131 system that confines the Au precursor and IO NPs in close
proximity to facilitate Au shell formation. The emulsion consists of an organic solvent, a
surfactant such as CTAB or poly(vinylpyrrolidone) (PVP), and an aqueous mixture of FeCl3,
15

FeCl2 and HAuCl4. IO NPs are first formed inside the micelle by coprecipitation through the
addition of basic solution such as sodium hydroxide. Then, a reducing agent, typically NaBH4, is
added to reduce HAuCl4 on the surface of the IO NPs to form Au shells. Coprecipitation is the
simplest way to make IO NPs without the need for capping materials. However, making
monodisperse IO NPs via coprecipitation is difficult. Monodisperse IO NPs are usually produced
by the thermal decomposition of Fe precursors at high temperatures.132, 133 These NPs are capped
with oleic acid (OA) and/or oleylamine (OAm) and are only dispersible in organic phase. Thus,
the direct deposition of Au atoms onto the IO NPs must be performed in organic phase.98, 105, 134138

For example, Wang et al. synthesized IO-Au core-shell NPs by heating a mixture of OA-

capped Fe3O4 NPs, Au acetate (Au(OOCCH3)3) and 1,2-hexadecanediol in phenyl ether to 180190oC for 1.5h.134 Xu et al. coated Au onto OA- and OAm-capped IO NPs at room temperature
by gently reducing HAuCl4 in a chloroform solution containing OAm.135 OAm served as a mild
reducing agent as well as a surfactant. To make water-soluble core-shell NPs, the as-prepared
IO-Au NPs were dried and then dissolved in an aqueous solution containing CTAB and sodium
citrate. The water-soluble IO-Au NPs can then be used as seeds for the growth of an Au shell.
This subsequent Au shell growth was readily achieved by the reduction of HAuCl4 by ascorbic
acid in the presence of CTAB. By adjusting the amount of HAuCl4, the thickness of Au shell can
be finely controlled. Spherical IO-Au core–shell NPs generally exhibit LSPR in the UV-Vis
region. In 2010, Jin et al. developed a method to make spherical IO-Au core-shell NPs with NIR
absorption by separating IO and Au by an organic gap (Figure 2.1B).120 They first modified OAcapped Fe3O4 NPs with amphiphilic phospholipid-polyethylene glycol terminated with
carboxylic acid. This allowed the particles to be dissolved into aqueous phase. Then, the particles
were coated with poly-L-histidine that chelates Au3+. The poly-L-histidine is capable of
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immobilizing Au3+ on IO NPs with high packing density. The multilayer organic molecules
prevent Au3+ from direct growth on the IO core. Subsequent reduction of chelated Au3+ led to the
formation of thin layer of Au shell (1-5 nm) within 1 h, with a clear separation from the IO core.
The total size of the IO-Au core-shell NPs was only around 35 nm with LSPR wavelength over
600 nm. This method enables the preparation of compact and monodisperse IO-Au NPs with
NIR absorption.
Au-seeded growth methods. To facilitate Au shell growth, small Au NPs (<10 nm) can be
adsorbed on the surfaces of IO NPs to serve as nucleation sites for the initiation of Au shell
growth. This Au-seeded growth method has been previously used to grow Au shells on silica (Si)
NPs by the Halas group.139, 140 Typically, Au seeds are adsorbed onto IO NPs via electrostatic
interactions. Since citrate-capped Au seeds are negatively charged, the surfaces of IO NPs need
to be positively charged. One way is to modify IO NPs with APTMS, a method similar to the
preparation of Si-Au core-shell NPs.99, 141, 142(Figure 2.2A). In this approach, OA-capped IO NPs
are first modified with tetraethyl orthosilicate (TEOS), which serve as anchor points for APTMS,
via the sol-gel process. APTMS functionalization is performed by silane ligand exchange. Au
seeds (2-3 nm) are prepared by the reduction of HAuCl4 by
tetrakis(hydroxymethyl)phosphonium chloride (THPC) followed by 1-2 weeks of aging at 4oC.
They are then attached to the PTMS modified IO NPs via the amino groups after incubation for
overnight at 4oC in a basic medium. One day prior to the shell growth, an Au hydroxide solution
is formed by the hydrolysis of HAuCl4 with potassium carbonate. The Au-seeded IO NPs are
added to the Au hydroxide solution, followed by the addition of formaldehyde to initiate Au shell
growth. The change of the solution color from colorless to blue indicates the growth of the Au
shell. The growth process is complete within 1 h. Although this method can lead to uniform IO-
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Au core-shell NPs; the process is time consuming, requiring days to complete a more expeditious
Au-seeded growth method is to use positively charged poly (allylamine hydrochloride) (PAH) to
adsorb the Au seeds, an approach developed in 2008 by Wang et al.143 In this approach, Fe3O4
NPs of ~260 nm in diameter were prepared through a solvothermal method using FeCl3 as the
Fe precursor and sodium acetate as the alkali. A thin layer of polymer with carboxyl terminal
groups was formed in situ by the copolymerization of acrylamide and methacrylic. The
copolymer surface was coated with PAH via electrostatic interaction to introduce amine groups
to attract the citrate capped Au seeds. The gold nanoparticles used as seeds were prepared by
reducing HAuCl4 with NaBH4 in the presence of sodium citrate. After adsorption of the citratecapped Au seeds, the Au shell was formed by reducing HAuCl4 with NH2OH in the presence of
the Au-seeded Fe3O4 NPs. Sequential reductive deposition steps led to uniform Au shell
formation. These reduction reactions were performed under ultrasonication in an ice bath to
prevent aggregation of the ferromagnetic Fe3O4 NPs.
Polyethyleneimine (PEI) is another positively charged polymer that is often used to
attract negatively charged Au seeds.76, 112, 144 In 2009, Goon et al. developed an approach to
directly make PEI-coated IO NPs and grew Au shells via repeated hydroxylamine reduction
deposition on the PEI coated IO NPs (Figure 2.2B).144 IO NPs were prepared by precipitation of
iron sulfate in a basic solution followed by oxidization with potassium nitrate at 90oC in the
presence of branched PEI (MW ~25 000) in an oxygen-free environment. This method led to 50
nm cubic Fe3O4 NPs capped with PEI, allowing for the direct attachment of citrate-capped Au
seeds in aqueous phase. 2 nm citrate-capped Au NPs were attached to the PEI-capped Fe3O4 NPs
by mixing via stirring for 2 h. The surface coverage of PEI was critical to the loaded density of
Au seeds, with a saturated amount of PEI at 0.88 mg PEI per cm2 on the particle surface leading
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to the highest Au-seed density (47.7 wt%). The Au-seeded Fe3O4 NPs were further coated with
another layer of PEI by mixing the particles in PEI solution for 1 h at 60oC. Thus, the Au seeds
were sandwiched on the surface of IO NPs with two layers of PEI, ensuring a high density of Au
seeds. The Au shells were then grown by iterative reduction of HAuCl4 onto the PEI-Au seedsPEI-IO NPs using NH2OH as the reducing agent. A total of five iterations were performed to
achieve a continuous Au shell. It is worthy to mention that the whole process was conducted in
aqueous solution. In addition, the Au shell is free of capping agent, allowing for facile surface
modification.

A
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Figure 2.2. Synthesis of IO-Au core-shell NPs via Au-seeded growth methods. (A) APTMS and
(B) PEI are used as the anchor agent for the adsorption of Au seeds on IO NPs. (A) is reprinted
with permission from ref. 99. Copyright (2007) American Chemical Society. (B) is reprinted
with permission from ref. 145. Copyright (2009) American Chemical Society.

2.2.

Synthesis of anisotropic IO-Au core-shell NPs
Anisotropic NPs offer many advantages over spherical NPs due to their well-known

geometry- dependent LSPR properties. For example, the local field enhancement on anisotropic
NPs can be orders of magnitude higher than spherical ones. For instance, the E-field
enhancement of Au tripod nanocrystals is 20 times higher than that of spherical NPs.145 A direct
outcome of this field enhancement is the strong augmentation of the Raman signals of adsorbed
molecules as the intensity of Raman signals is proportional to the fourth power of the local field
of the metal particle.146 An enhancement factor on the order of 104 to 105 was observed for the
Raman signals of adsorbed molecules on Au nanorods (NRs), while no such enhancement has
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been observed for the adsorbed molecules on Au nanospheres under similar condition.147 In
addition, the anisotropic NPs can extend the optical properties from the visible to the NIR region
without changing particle size.145 The NIR window is extremely important for biomedical
applications as light in this region is tissue penetrative.148 Thus, synthesis of anisotropic NPs
with IO cores is extremely attractive. A direct method to make anisotropic IO-Au core-shell NPs
is to use anisotropic IO NPs as the core materials; the resulting core-shell NPs preserve the shape
of the IO NPs. In 2006, Halas and co-workers reported the synthesis of IO-Au core-shell
nanorice using an Au-seeded method (Figure 2.3).149 In their studies, monodisperse hematite
nanorice with aspect ratio of 6.3 (length = 340 nm. Diameter = 54 nm) were fabricated by
heating FeCl3 and potassium dihydrogen phosphate at 100oC for 72 h. The nanorices were
functionalized with APTMS to generate the amine groups to adsorb THPC-capped Au seeds. The
growth of the Au shell was performed by the reduction of HAuCl4 by formaldehyde in an
aqueous solution containing the Au-seeded nanorice at room temperature. The growth of
complete Au shells took only 5-10 min. Au shells from 10 to 30 nm were formed by adjusting
the ratio of the hematite nanorice and HAuCl4. The hematite nanorice have the combined
plasmonic properties of nanorods and nanoshells in the NIR region, making them very promising
for biomedical applications.
Making anisotropic IO-Au core-shell NPs with anisotropic IO NPs is simple and can
preserve the shape of the cores. However, when the size of the IO NPs is small, it is difficult to
grow the Au shell while preserving the shape of the core. For example, the use of 60 nm
tetracubic IO NPs as the cores resulted in spherical IO-Au core-shell NPs.142 An approach for
preparing anisotropic IO-Au nanostars (NSTs) was developed by Wei and co-workers using
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Figure 2.3. Synthesis of IO-Au core-shell nanorices via an Au-seeded growth method.
(A) Schematic of the preparation of IO-Au core-shell nanorices. (B-E) SEM (left) and
TEM (right) images of IO-Au core-shell nanorices at different preparation steps. (B)
The IO nanorices. (C) Au-seeded IO nanorices. (D) IO-Au core-shell nanorices with
thin shells (~13 nm). (E) IO-Au core-shell nanorices with thick shells (~28 nm).
Reprinted with permission from ref 150. Copyright (2006)
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spherical Fe3O4 NPs as the cores (Figure 2.4).150,151 Spherical Fe3O4-Au core-shell NPs of 8.4-13
nm were first prepared in organic phase at 190oC by the reduction of gold chloride (AuCl3) by
1,2-hexadecanediol in octyl ether containing 8.4 nm OA and OAm-caped IO NPs (8.4 nm). This
shell was only ~1.3 nm in thickness. The Fe3O4-Au core-shell NPs with thin Au-shells were
introduced into a growth solution containing HAuCl4, CTAB, silver nitrate (AgNO3), and
ascorbic acid (AA). This growth solution has been widely used to make anisotropic metallic NPs
such as Au NRs due to the shape directing CTAB surfactant and AgNO3 additive.152 AA is a
surface-catalyzed reducing agent, which prevents formation of solid Au NPs. Thus, anisotropic
IO-Au NSTs were obtained. This is the first report of the synthesis of monodisperse IO-Au coreshell NSTs. We recently developed a facile method for the synthesis of uniform IO-Au core-shell
NSTs with all steps performed in aqueous solution and this study will be further explored in
detail in chapter three.
Shi and co-workers reported another approach to making IO-Au NSTs using Ag-seeded
IO NPs.101 In their study, small Ag NPs were synthesized for the seeds via the reduction of
AgNO3 by NaBH4 in a partially thiolated PEI (PEI-SH) aqueous solution. The PEI-stabilized Ag
NPs were added into a mixture of FeCl2 and ammonium hydroxide and autoclaved in a sealed
pressure vessel at 134oC for 3 h to obtain Ag-seeded Fe3O4 NPs. This hydrothermal process led
to the homogenous coating of Au NPs on the Fe3O4 NPs. Addition of the Ag-seeded Fe3O4 NPs
into a growth solution containing HAuCl4, CTAB, AgNO3 and AA resulted in the formation of
Fe3O4-Au core-shell NSTs within 1 h.
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Figure 2.4. Synthesis of IO-Au core-shell NSTs. Synthesis of IO-Au core-shell NSTs from small
IO-Au core-shell nanospheres. (Top) Schematic of the preparation procedure. (Bottom) TEM
image of IO NPs (left), HRTEM image of a tip (middle), and TEM image of IO-Au NSTs.
Reprinted with permission from ref 152. Copyright (2010) American Chemical Society

2.4.

Growth mechanism
A common model to understand the growth mechanism of anisotropic solid Au NPs is

that the Au seeds are faceted NPs. The formation of various shapes is the outcome of the
interplay between the facet binding tendency of the stabilizing agents and the growth kinetics.153
As for the core-shell NPs, Halas and co-workers have studied the growth mechanism of spherical
Au nanoshell on silica core by monitoring the progression of Au nanoshell formation with TEM
imaging.139 Their studies showed that at the early stages the adsorbed Au seeds gradually grew
with time on the silica core, then coalesced on the core surface until finally forming a continuous
metallic shell. In the studies of IO-Au NSTs prepared from spherical IO-Au NPs, Wei and
coworkers used high resolution TEM (HRTEM) and found multiple twinning defects and overall
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growth along the (111) directions. As the mismatching of crystal lattices of Au and IO are within
3%, it is believed that the formation of the shell is due to favorable epitaxial growth. The growth
of the Au-seeded IO NPs into anisotropic was due to the effects by AgNO3. AgNO3 has been
widely used to assist the preparation of Au NRs and other anisotropic metal NPs.154-156 It has also
been used to form spiky Au nanoshells from an Ag seeded polymer template.157,158A previous
model to explain the role of Ag+ is silver underpotential deposition, the reduction of Ag+ to Ag0
on a metal substrate with a surface potential less than the standard reduction potential.159 Based
on this model, Ag+ is reduced and deposited onto the surfaces of Au seeds in the presence of a
reducing agent.
2.5.

Properties

2.5.1. Magnetic properties of IO-Au core-shell NPs.
Due to the unpaired electrons in the 3d shell of Fe2+ and Fe3+, nanocrystals formed from
Fe2+ and Fe3+ can be in ferromagnetic, ferrimagnetic and antiferromagnetic states. In
ferromagnetic materials, the magnetic moments of two sublattices align parallel to each other
even without an external field. In ferrimagnetic materials, the magnetic moments align
antiparallel, but do not cancel each other out. This is different from the antiferromagnetic
materials where the magnetic moments of two sublattices are equal and align antiparallel. Thus,
there is no net magnetic moment in zero magnetic field for antiferromagnetic materials. The
magnetic moments lose ordering beyond a specific temperature called the Curie temperature TC
for ferromagnets and ferrimagnets and the Neel temperature TN for antiferromagnets. Magnetite
Fe3O4 is a well-known ferrimagnetic material with a TC of 858 K.160 Maghemite γ-Fe2O3 is
ferrimagnetic at room temperature. They are unstable at high temperatures and thus TC is hard
to determine. Both Fe3O4 and γ-Fe2O3 NPs are superparamagnetic at room temperature when
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their sizes are sufficiently small (less than 30 nm).96,161-163 For the superparamagnetic NPs, the
magnetization randomly flips directions due to thermal fluctuations and shows zero net
magnetization at zero magnetic field. The particles behave like paramagnetic material under an
external field, but their magnetic susceptibility is much larger than that of paramagnets.
The magnetic properties of IO NPs depend on the surface. When the size of the NPs
decreases, the magnetic properties decrease due to increased surface effects. Passivation with
organic and inorganic layer helps decrease the surface effect, but it could also adversely affect
the surface magnetic moment of IO NPs. The surface magnetic moments of IO NPs can be
disordered via the interaction with Au electrons.164 The IO-Au core-shell NPs could have larger
surface effect than IO NPs by structural distortions that cause spin canting.136,165 This leads to
decreased magnetic properties of the IO-Au core-shell NPs compared to the IO NPs. Magnetic
properties are commonly measured by a superconducting quantum interference device by
scaling to the total mass of the materials. Au has 4 times higher density than IO. However, Au is
diamagnetic in bulk states. It is ferromagnetic when the size very small (4-5 nm).166 Therefore,
IO-Au core-shell NPs generally give significantly lower saturation magnetization (Ms) than IO
NPs due to the mass contribution from the diamagnetic Au shell. For example, coating the
tetracubic IO NPs (~60 nm) with a 10.9 nm Au shell decreased the Ms from 20 to 0.6 emu g-1 at
both 100 K and 250 K (Figure 2.5.A and B).142 Coating 258 nm Fe3O4 NPs with a 7.5 nm Au
shell decreased the Ms from 75.6 to 61.0 emu g-1.143 The IO-Au core-shell NPs typically exhibit
the same magnetic behavior as the IO core. Increasing Au shell would lead to a decrease in the
magnetic properties of the core-shell NPs due to the mass contribution of the diamagnetic Au.
Studies by Crespo et al. showed that the charge transfer between a thiol ligand and an Au
surface was a major reason for the observed ferromagnetic properties of thiolated Au NPs.166 It
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has also been recognized that the magnetic material could spin polarize the Au conduction
electrons at the IO-Au interface and thus result in magnetization of the surrounding
nonmagnetic Au.167 In addition, a large orbital magnetic moment could be induced at the Fe3O4Au interface. This interface effect leads to the magnetization enhancement of Fe3O4 NPs by a
factor of six (Figure 2.5.C).122 studies have shown that there is no significant difference in the
coercivity between coated and uncoated IO NPs.142 However, enhanced coercivity has been
reported by Pal et al. on small Fe3O4 NPs (6 nm) with ultrathin shell (1 nm thickness).136 NPs
had Hc of 160 Oe at 5 K. The coercivity enhancement is possibly due to the role of spin
disorder at the Fe3O4-Au interface and weak exchange coupling between surface and core spins.
Separation of IO-Au core-shell NPs from suspension usually takes much longer than uncoated
IO NPs because of the massive amount of Au added to the IO NPs by the Au shell. This can be
theoretically understood by calculating the particle terminal velocity under external magnetic
field. The particle terminal velocity V is equal to V =

𝐹𝑚
6𝜋𝜂𝑅

where Fm is the magnetic force

exerted onto the particle by the external magnetic field, 𝜂 is the viscosity of the solution, and R
is the hydrodynamic radius of the particle. The Fm of the IO-Au core-shell particle is the same
as the IO particle if Au coating does not affect the magnetic property of the IO core. Thus, the
particle terminal velocity V is inversely proportional to the hydrodynamic radius R of the
particle. The Au-coated Fe3O4 NPs gave a coercivity Hc of 200 Oe while the uncoated Fe3O4.
The particle also takes time to reach the terminal velocity. The time, called relaxation time τ is
equal to τ = m / (6 π η R) where m is the mass the particle. This means that τ is linearly
proportional to the mass of the particle and is inversely proportional to the hydrodynamic radius
of the particle. Considering both V and τ from the above two equations, the time taken for a
particle to be separated by an external magnetic field is therefore proportional to the mass of the
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Figure 2.5. Magnetic properties of IO-Au core-shell NPs. (A-B) Magnetization as a function of
applied field at 100 K and 250 K for uncoated and Au coated tetracubic IO NPs. Reprinted with
permission from ref 143. Copyright (2009) American Chemical Society. (C) Magnetization as a
function of applied field at 10 K for IO-Au core-shell nanopopcorns of three different sizes.
Reprinted with permission from ref 76. Copyright (2016) American Chemical Society. (D)
Magnetization as a function of applied field at 10 K and 300 K for bare IO NPs (sample A), IOAu core-shell NPs with low Au (sample B) and high Au (sample C). Reprinted with permission
from ref 122. Copyright (2011) American Chemical Society.
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NP. The mass of IO and IO-Au core-shell NP can be calculated based on their sizes measured by
TEM and the densities of IO (5.24 g cm-3) and Au (19.32 g cm-3). If an IO NP is 20 nm in
diameter and the Au shell is 10 nm, the mass of IO-Au core-shell NPs is 27 times Larger than the
IO NP. This means that the separation time for a core-shell particle is roughly 27 times longer
than that of the IO NP traveling the same distance. Thus, if an IO NP takes 5 min to be separated
from the solution, the separation of an IO-Au core-shell NP requires more than 2 h due to the
mass added by the diamagnetic Au shell.

2.5.2. Optical properties of IO-Au core-shell NPs
The optical properties of core-shell plasmonic NPs have been a topic of great interest in
materials science for many years. Their properties are dependent on the dielectric functions of
the core and shell materials, the core size and shape, as well as the shell thickness and geometry.
An intensely studied core-shell NP is the Au nanoshell with a silica core pioneered by Halas and
co-workers.168 The Si-Au core-shell NPs exhibit strong NIR properties, with increasing
thickness of the Au shell leading to an LSPR blue shift.139 They proposed a hybridization model
to understand the plasmons of concentric nanoshells, where the hybridization of the plasmons of
inner and outer nanoshells determines the LSPR of the Si-Au core-shell NPs.169
Using Mie theory, Shaffin et al. calculated the optical properties of spherical Fe3O4-Au
core-shell NPs, and compared them with Si-Au, Co-Au, hollow Au, and solid Au NPs (Figure
2.6A).170 Compared with solid Au NPs of the same size, the LSPR peak of IO-Au core-shell
NPs is further red shifted than those of silica and hollow NPs. The LSPR peak intensity is
comparable to that of solid Au NPs, but much lower than those of the hollow Au and Si-Au
core-shell NPs. In contrast, the Co-Au core-shell NPs have very weak plasmon peaks, although
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cobalt NPs have stronger magnetic properties than magnetite NPs. These optical differences can
be traced to the differences in the dielectric properties of the core material, which is related to
the refractive index of the material. IO NPs are nontransparent and have complex refractive
indices. Silica, on the other hand, is a non-absorbing material and has only a real refractive
index. While the LSPR peak wavelength is determined by real component of the refractive
index of the material, the peak intensity is determined by the imaginary component of the
refractive index. Increasing the real refractive index leads to a red shift of the LSPR peak
whereas increasing the imaginary refractive index leads to a reduction of the peak intensity
(Figure 2.6B). Indistinguishable to Si-Au core-shell NPs, the LSPR wavelength blue shifts with
the increase of Au shell thickness when the total diameter of the NPs is fixed (Figure 2.6C and
D). It follows the same universal scaling as the Si-Au core-shell NPs that has been reported by
Jain and El-Sayed.171 The shift in LSPR wavelength is determined by the ratio of the thickness
of the shell to the radius of the core (t/R). Compared to the Si-Au system, the Fe3O4-Au NPs
show a larger decay constant in the plasmon shift versus the ratio of shell thickness. This is
consistent with LSPR peaks that are more red-shifted than those of Si-Au NPs having identical
shell thicknesses and core radii. In typical IO-Au NP synthesis, the IO-core diameter remains
constant; as the Au shell thickness increases, the total particle size increases as well. In this
case, the LSPR peak is seen to blue shifted first with increasing the thickness of the Au shell
(Figure 2.6E and F). However, as the thickness of the Au shell continues to grow, a red shifted
of the LSPR peak occurs. In this case, the peak shift seems do not adhere to the universal
scaling equation. When the Au NPs with the same diameter of each core-shell NP are used as
the references, the data follows the universal scaling nicely.
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Figure 2.6. Calculated optical properties of Fe3O4-Au core-shell NPs. (A) Extinction spectrum
of Fe3O4-Au core-shell NPs in comparison with other core-shell NPs and solid Au NPs with the
same diameter Dtotal = 50 nm of NPs and a shell thickness of 5nm. (B) Extinction spectra of coreshell NPs with varied core refractive indices. (C) Extinction spectra of Fe3O4-Au core-shell NPs
with different shell thickness with fixed total particle size. Dtotal = 50 nm. (D) Fractional shifts
(Δλ/λ0) of the LSPR peak maximums of the IO-Au NPs from (C). (E) Extinction spectra of
Fe3O4-Au core-shell NPs with different shell thickness with fixed IO core size. Dcore = 15 nm. (F)
Fractional shifts (Δλ/λ0) of the LSPR peak maximums of the IO-Au NPs from (E). Reprinted
with permission from ref 171. Copyright (2014) American Chemical Society.

Theoretically, a spherical IO-Au core-shell NP with a 20 nm core and a 15 nm shell has a
LSPR peak at 540 nm.170 When the core is increased to 35 nm and Au shell thickness is
decreased to 7.5 nm, the LSPR is red shifted to 650 nm. Most existing IO NPs are 30 nm and
less. Thus, they have LSPR in the UV-Vis region after Au coating. To make particles with LSPR
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over 800 nm, the core needs to be larger than 100 nm assuming shell thickness t is equal to or
larger than 5 nm.171 NIR-absorbing IO-Au NPs less than 50 nm have been reported by Gao and
co-workers (Figure 2.7A).120 These particles have a core and shell separated by a few nanometer
polymer gap. Although the core is only 25 nm in diameter, the particles absorb over 700 nm
when the Au shell is 2-3 nm. When the shell is decreased to 1-2 nm, the particles show a broad
absorption band with the plasmon resonance approximately 850 nm. This is consistent with our
computational studies that demonstrated a polymer gap induce plasmon red shift.
A common way to tune the LSPR of plasmonic NPs is to change the shape. For example,
when an Au NP is changed from sphere to rod, the LSPR is split into two peaks.90 One is around
520 nm (transverse band) resulting from the electron oscillations along the short axis of the rod.
The other one (longitudinal band) is at a longer wavelength with much stronger intensity due to
the electron oscillations along the long axis. The LSPR of this longitudinal band is very sensitive
to the article's aspect ratio (length/width). Increasing the aspect ratio causes large shift of the
LSPR wavelength into NIR region. IO-Au core-shell nanorods have not been experimentally
produced. Theoretically, Brullot et al. calculated the optical properties of IO-Au core-shell NPs
with different aspect ratios using discrete dipole approximation (DDA) (Figure 2.7B).26 For an
IO-Au NR with fixed size (Reffective =10 nm) and core to total volume (Vcore/Vtotal = 0.2) the
longitudinal LSPR shifts from 520 to 1000 nm when the aspect ratio increases from 1 to 5,
accompanied by over 20-fold increase in the extinction efficiency. Core-shell nanorice have been
reported by Halas and co-workers.149 The nanorice (core length =340 nm. Core diameter =54
nm) have a weak transverse resonance at a wavelength lower than 800 nm and a strong
longitudinal resonance over 1000 nm. These plasmon resonances are the result of the
hybridization of the parent spheroid and cavity plasmon resonances corresponding to the aspect
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ratio of the particle. When the thickness of Au shell is increased from 9.8 to 27.5 nm, the
longitudinal resonance blueshifts from 1300 nm to 1100 nm.
2.6.

Concluding remarks and future perspectives
Due to the combined optical and magnetic properties, IO-Au core-shell NPs are of

considerable interest in many fields, ranging from materials science to biology and medicine.
Synthesis of uniform IO-Au core-shell NPs with desirable magnetic and optical properties are of
extreme importance for their technological applications. During the past decade, the majority of
studies have been focused on the preparation of spherical core-shell NPs. Two classes of
approaches have been used: direct reductive deposition of Au onto IO cores and Au seeded
growth methods. The Au shell is formed either by epitaxial growth or coalescence of Au seeds
on the surface of Au NPs. Anisotropic IO-Au core-shell NPs in several shapes have been
achieved either using anisotropic IO cores or by controlling the kinetic and dynamic parameters
in the growth solutions. IO-Au core-shell NPs generally exhibit the same magnetic behavior as
the cores with reduced saturation magnetization due to the mass contribution of the diamagnetic
Au. They show optical properties from the visible to the NIR region depending on the core size,
shell thickness, and shape. IO-Au core-shell nanostars exhibit multiple plasmon resonances due
to the coupling of the core and tip plasmons.
Despite the great progress in synthesis methods, the preparation of high-quality
anisotropic IO-Au core-shell NPs remains a major challenge. This is due to the difficulties in
controlling the Au shell geometry. For example, IO-Au core-shell nanostars have been reported
by several groups. But the samples are mixtures of stars with different numbers and dimensions
of tips. Compared with solid Au NPs, the shape control for IO-Au core- shell NPs is also limited.
New shapes with fine tuning of the optical properties will be sought-after in the near future. In
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addition, new nanostructures should have ultrathin Au shells in order to preserve the
advantageous magnetic properties of the core. The effect of the Au shell on the magnetic
properties of the IO core at the interface is also much less understood. IO-Au core-shell NPs
show similar optical trends to the prototype Si-Au core-shell NPs with their structural variations.
But more studies, especially computational studies are needed to understand the shape-dependent
optical properties. The computational studies can have precise structural control on the size and
shape of the nanoparticles. Calculated results will greatly help us understand the structurefunction relationship as well as the origins of the plasmon peaks.
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CHAPTER 3: Size and Shape-Controlled Synthesis and Properties of
Magnetic-Plasmonic Core-Shell Nanoparticles

3.1.

Introduction
With their combined magnetic and optical properties of their core and shell materials,

magnetic-plasmonic core-shell nanoparticles (NPs) are useful in many areas including optical
imaging,120, 172, 173 magnetic resonance imaging,172-177 biological separation,110, 178-184
molecular/cellular detection,115, 182-185and cancer treatment,173,100, 177,180,186, 187superior to solid
magnetic and solid plasmonic NPs. For the existing magnetic-optical core-shell nanostructures,
the core commonly consists of iron (Fe) or iron oxide (IO, Fe3O4 or 𝛾-Fe2O3) and the shell is
typically gold (Au) or silver (Ag). IO-Au core-shell NPs are particularly appealing because they
have combined magnetic and optical properties of IO and Au NPs that can be individually tuned
by changing the particle size and shape.188, 189 In addition, the Au shell is inert and allows for
facile surface modification.
During the past decade, a great deal of research efforts has been made on the synthesis of IOAu core-shell NPs in the spherical shape.188,189 The synthetic methods can be organized into two
major categories: (1) the reduction of an Au precursor in the presence of IO NPs with or without
surface modifications 190-193, and (2) the reduction of an Au precursor in the presence of Auseeded IO NPs.194-196 The second method is well received because the Au seed serves as the
nucleation site to facilitate the growth of the Au shell. However, current methods using Auseeded IO NPs often use a multistep deposition of Au atoms in order to form a uniform Au shell.
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Scheme 3.1. Synthesis of IO-Au Core-Shell NPs in Different Shapes. Au-seeded IO NPs were
prepared by electrostatic adsorption of small Au NPs onto PEI-stabilized IO NPs, followed by
further stabilization with PEI. The growth of IO-Au core-shell NPs was initiated by injecting Auseeded IO NPs into a growth solution containing chloroauric acid (HAuCl4), silver nitrate
(AgNO3), cetyltrimethylammonium bromide (CTAB), and ascorbic acid (AA).

Generally, the IO-Au nanospheres (NSPs) exhibit localized surface plasmon resonance
(LSPR) in the visible region, but large particles (>150 nm)142, 194, 196 or particles with a gap
between the core and shell197 show LSPR in the near infrared (NIR) region. Anisotropic NPs
offer greatly enhanced optical properties as compared with spherical counterparts due to their
high curvature structure. For example, the peak E-field enhancement factor ( E2/E02 ) of an Ag
nanoprism is about 10 times higher than that of an Ag NSP.145 This may lead to as much as 100
times stronger surface enhanced Raman scattering (SERS) signals for the nanoprisms as
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compared with the NSPs. Due to their strong SERS activities Au-based NPs in popcorn and star
shapes have been well used for SERS-based biomedical detections.198-202 Anisotropic NPs could
also offer new functions such as dynamic optical imaging because their optical properties are
sensitive to the polarization of the light.150 Additionally, anisotropic NPs allow for greater optical
tunability than spherical ones. For example, the LSPR wavelength of Au nanorods (NRs) can be
tuned from 620 to 960 nm by increasing the particle’s aspect ratio from 2.4 to 5.7.203 In contrast,
the LSPR wavelength of Au NSPs can only shift from 520 to 570 nm when the size is increased
from 9 to 99 nm.204
Despite the compelling anisotropy-associated properties and functions, the ability to
synthesize and understand anisotropic IO-Au core-shell NPs remains very limited. In 2006, the
Halas group synthesized IO-Au core-shell nanorices via a seed-mediated growth method.194 The
use of large rice-shaped IO NPs (longitudinal diameter over 300 nm) resulted in Au-coated IO
NPs of the same shape. Later, the Wei group reported for the first time of the synthesis of starshaped IO-Au core-shell NPs.151 In their method, IO-Au core-shell NSPs (9-16 nm) were firstly
prepared in organic phase at high temperature by the reduction of Au3+ in the presence of small
IO NPs (8-13 nm). These IO-Au core-shell NSPs were then used as seeds to form IO-Au coreshell NPs in a star shape. In recent studies, Bhana et al. synthesized IO-Au core-shell NPs in
pin205 and oval shapes.113 using Ag-seeded IO nanospheres as the seeds. Although these
anisotropic NPs are compact in size (less than 100 nm), they are polydisperse and often
contaminated with a large portion of spheres.
Here we report the facile synthesis of monodisperse IO-Au core-shell NPs of three
different shapes, sphere, popcorn, and star, through a fine control of the thermodynamic and
kinetic parameters of the seed-mediated growth method. We also demonstrate the tunability of
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the Au shell thickness for each shape, producing anisotropic NPs less than 100 nm. By
combining experimental and computational approaches, we have gained a deeper understanding
of the mechanism for the shape-controlled synthesis as well as the structure-property relationship
of the resultant NPs. Our studies have not only made much progress in manipulating and
understanding the magnetic-plasmonic core-shell nanosystem but also provided a panel of highquality bifunctional nanostructures for biomedical detection and treatment.
3.2.

Experimental and Theoretical Methods

3.2.1 Materials and Methods. All chemicals were purchased from Sigma Aldrich unless
specified.
3.2.2. Synthesis of IO NPs. Octahedral IO NPs were synthesized according to the method of
Goon et al.144 with modifications. In a typical procedure, 175 mg of iron sulfate (FeSO4), 2.5
mL of 2.0 M potassium nitrate (KNO3), 2.5 mL of 1.0 M sodium hydroxide (NaOH), and 5 mL
of 8 mg/mL polyethylenimine (PEI, branched, MW ∼ 25 000) were added to 20 mL of nitrogenpurged ultrapure water. Under the oxygen-free environment, the mixture was heated to 90°C
under vigorous stirring, with continued heating at this degree for 2 h. During the heating process,
the solution changed color from blue to black, indicating the formation of IO NPs. The NPs were
purified by magnetic separation for five cycles and then redispersed in 20 mL of ultrapure water
for further use.
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Figure 3.1. Structural and magnetic characterizations of IO NPs. (A-C) TEM images, (D) DLS
plot, (E) HRTEM image, (F) powder XRD pattern, (G) EDS spectrum, and (H) magnetization as
a function of applied field at room temperature. Inset in (H): Optical images of IO NPs with a
permanent on at t = 0 and t = 5 min. Image in (A) was taken on a JEM-1200 TEM microscope.
Images in (B), (C), and (E) were taken on an FEI Titan HRTEM.
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3.2.3.

Synthesis of Au-Seeded IO NPs.
Similar to the method by Goon et al.,144 we attached Au seeds to IO NPs to facilitate the

growth of the Au shell. First, small Au NPs were synthesized by reduction of chloroauric acid
(HAuCl4, 25 mM) with sodium borohydride (0.02 M) in the presence of sodium citrate (0.85
mM). Then, they were attached to PEI-stabilized IO NPs via electrostatic interactions (scheme
1, step 1). In a typical procedure, 55 µL of 0.32 mg (Fe) of PEI-stabilized IO NPs was added to
5 mL of as-prepared Au NPs and stirred for 45 min. After purification by three cycles of
magnetic separation and washing, the solution was redispersed in 2.5 mL of 15 mg/mL PEI
aqueous solution and heated at 60 °C for 3 h. After purifications by three cycles of magnetic
separation and washing, the Au-seeded IO NPs were redispersed in 1 mL of ultrapure water for
further use.
3.2.4. Synthesis of IO-Au Core-Shell Nanospheres (NSPs), Nanopopcorns (NPCs), and
Nanostars (NSTs). (scheme 1, Step 2). To make IO-Au core-shell NSPs, an Au growth solution
was prepared by adding 200 µL of 10 mM HAuCl4 into 5 mL of 0.1 M
cetyltrimethylammonium bromide (CTAB) aqueous solution. After mixing for 5 min, 32 µL of
100 mM ascorbic acid (AA) was added to reduce HAuCl4 to HAuCl2. Then, Au-seeded IO NPs
with different amounts from 100 to 800 µL were injected. The solution was stirred for 10 s
followed by incubation for 2 h to allow complete growth of IO-Au core-shell NPs. To make
NPCs, the same procedure was used except 30 µL of 10 mM silver nitrate (AgNO3) and 90 µL
of 100 mM AA were added into the growth solution. To make NSTs, the amount of AgNO3 was
the same as the NPCs, but the amount of AA was decreased to 32 µL, the same as NSPs.
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3.2.5.

Characterizations. All the as-prepared NPs were subjected to purification by

magnetic separation before characterizations. The absorption spectra of all the NPs were
collected using a VIS-NIR absorption spectrometer (Ocean Optics, Dunedin, FL). The magnetic
properties of IO NPs were measured using a vibration sample magnetometer (Dexing Magnets,
China) and those of IO-Au core-shell NPs via a quantum design superconducting quantum
interference device (SQUID). Magnetic separation was performed with Qiagen 12-tube
magnets. The size and morphology of the NPs were examined with a JEM1200EX II
transmission electron microscope (TEM) (JEOL Ltd., Tokyo, Japan). Hydrodynamic size (HD)
and zeta potential (ξ) were determined by dynamic light scattering (DLS) with a Particle Size
Analyzer (Brookhaven Instruments Corp, NY, USA). Energy-dispersive X-ray spectra (EDS)
were taken on a Nova NanoSEM 640 (FEI, Hillsboro, Oregon). High-resolution TEM
(HRTEM) images were taken on an FEI Titan HRTEM (FEI, Hillsboro, Oregon).

3.2.6.

First-Principles Calculation. We used the Perdew Burke-Ernzerhof (PBE)206

version of the generalized-gradient approximation (GGA) exchange-correlation functional to
calculate the adsorption energy of Ag on Au surfaces. We use projector-augmented-wave
(PAW) potentials207 and a planewave basis as implemented in the Vienna Ab-initio Simulation
Package (VASP) code.208 The kinetic energy cutoff of the plane wave basis is set to be 229.9
eV. The electronic self-consistent calculations are converged to 10-4 eV between two selfconsistent steps. The structural relaxations are converged to 10-3 eV for the total energy
difference between two ionic steps. All the adsorption energies are calculated for
on the corresponding Au surfaces.
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3.2.7. Discrete Dipole Approximation (DDA) Calculation. The IO-Au NSP, NPC, and
NST extinction spectra were calculated using the widely used DDA method as implemented
by the DDSCAT 7.3 software.209,210 The Au shells and IO (Fe3O4) cores were modeled using
complex dielectric response functions of Johnson and Christy211 and Goossens et al.,212
respectively. We developed a Fortran 90 code for the generation of the particle
representations as material-specific point dipoles on a cubic lattice for the subsequent DDA
calculations. The IO cores are represented as regular octahedrons with a specified edge
length within an Au sphere of a specified diameter. Au conical tips are added to the surface
of the spheres with additional dipoles added such that there are no gaps between the conical
tips and the sphere surface. A sufficient number of dipoles (>106) were used in all
calculations to achieve sufficient convergence of the calculated spectra.
3.3.

Results and Discussion

3.3.1. Synthesis and Properties of IO NPs. To make IO NPs, ferrous hydroxide (Fe (OH)2)
was first formed by precipitation of FeSO4 in a basic solution and then oxidized to Fe3O4
with KNO3 at 90 °C in the presence of branched PEI in an oxygen-free environment. This
method leads to aqueous soluble IO NPs with positive charges that allow for subsequent
adsorption of negatively charged Au seeds. The DLS measurement showed a zeta potential
around +34 mV, indicating the stabilization of the IO NPs by the positively charged PEI.
TEM and SEM images showed that the IO particles had an octahedral shape, with average
edge lengths of 35 nm (from ∼100 NPs) (Figure 3.1A-C).
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Figure 3.2. Structural and optical characterizations of Au-seeded IO NPs. (A) TEM image, (B)
DLS plot, (C) absorption spectra, and (D) HRTEM image.
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The particles were well dispersed in water, giving an average HD of 52 nm (Figure
3.1D). HRTEM imaging revealed that the NPs were single crystals (Figure 3.1E). X-ray
diffraction analysis showed that they were composed of Fe3O4 (Figure 3.1F). EDS showed the
characteristic Fe Kα1 peak at 6.4 keV (Figure 3.1G). The particles exhibited ferromagnetic
properties, with a saturation magnetization Ms around 90 emu/g, a coercivity of 250 Oe, and a
retentivity of 20 emu/g (Figure 3.1H). A complete separation of the particles from the aqueous
solution was observed within 5 min after the attachment of a Qiagen 12-tube magnet to the vials
containing the particle solution (Figure 3.1H, inset). This further confirmed the strong magnetic
properties of the IO NPs.
3.3.2. Synthesis and Characterization of Au-Seeded IO NPs. In order to form an Au shell on
the IO NPs, small Au NPs (<10 nm) capped with citrate were adsorbed to the PEI-stabilized IO
NPs to serve as the nucleation sites (see Scheme 1, Figure 3.2A). The negatively charged Au
seed bound to the positively charged IO NPs via electrostatic interactions. Goon et al. have
shown that the amount of PEI on IO NPs is an important factor in determining the surface
density of the Au seed, with an increased amount of PEI leading to increased Au density.213 We
found that the stabilization of the Au-seeded IO NPs with additional PEI was also crucial to
achieve a high-density Au seed. Without applying PEI after Au seed adsorption, the IO NPs were
found to have a low surface density of the Au seed (Figure 3.3). In the presence of 5 mg/mL of
PEI, the surface density of the Au seed increased slightly. At 15 mg/mL PEI, the IO NPs were
fully coated with Au NPs. A further increase of the PEI concentration resulted in a decrease in
the Au seed density.
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These results demonstrate that sandwiching the Au seeds between two PEI layers is
essential to achieve Au-seeded IO NPs with high surface density. The Au-seeded IO NPs were
averagely 55 nm by TEM and 78 nm by DLS (Figure 3.2B). The HRTEM image showed that the
Au seeds are single crystals enclosed by 111 facets (Figure 3.2C). They showed a LSPR at 523
nm due to the adsorbed Au seed (Figure 3.2D).

A

B

D

E

C

F

Figure 3.3. The effect of PEI concentration on the adsorption of Au seed on IO NPs. (A) 0
mg/mL of PEI, (B) 5 mg/mL of PEI, (C) 10 mg/mL of PEI, (D) 15 mg/mL, (E) 25 mg/mL of PEI
and 30mg/mL of PEI
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Table 3.1. Experimental parameters for IO-Au Core-Shell Nanosphere (NSPs), Nanopopcorns
(NPCs) and Nanostars (NSTs)

Shape
Sphere

CTAB (M)
0.4

AA (mM)
0.64

AgNO3 (M)
0

Seed (L)
100, 400, 800

Popcorn

0.4

1.80

60

100, 400, 800

Star

0.4

0.64

60

100, 250, 350

3.3.3. Synthesis of IO-Au Core-Shell NSPs. IO-Au core-shell NPs of different sizes and
shapes were synthesized via a seed-mediated growth method. To form spherical particles, the
Au-seeded IO NPs were injected into a growth solution containing HAuCl2 (0.4 mM), CTAB
(0.1 M), and AA (0.64 mM). HAuCl2, CTAB, and AA served as the Au precursor, capping
agent, and reducing agent, respectively. HAuCl2 was prepared in advance by the reduction of
HAuCl4 with AA. The reduction of Au+ to Au0 by AA is a surface catalyzed reaction. Thus, IOAu core-shell NPs, rather than self-nucleated Au NPs, were preferentially formed in the presence
of Au-seeded IO NPs. The appearance of a pink color indicates the growth of the Au-seeded IO
NPs that completes within 1 h. Compared to the method by Goon et al.,213 this method only need
a single step to form a uniform Au shell from the Au-seeded IO NPs, avoiding cumbersome
iterative depositions.
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Figure 3.4. Characterizations of IO-Au core-shell NSPs of different sizes. (A) TEM
images of 77 nm (left), 110 nm (middle), and 140 nm (right) IO-Au core-shell NSPs. Each
size was determined by averaging the diameter from ∼100 NPs in a spherical geometry
(see inset illustration) from the TEM images. (B) DLS plots. (C) EDS spectra. (D) Optical
images of IO-Au NSP solutions before and after magnetic separation.
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Table 3.2. Characterizations of the Size Distribution of IO-Au Core-Shell NPs of Different
Shapes. Dav: the average diameter (∼100 NPs) of the IO-Au spherical base core measured by
TEM (see Figure 3.4A, 2.5A-2.6A) the left panel inset for illustration). σ (%): standard
deviation. Dhydro: the average hydrodynamic diameter measured by DLS. Ltip: the length of the
protrusions on the IO-Au spherical core. W1/2tip: the half length of the protrusions.

TEM size analysis
Dav
(nm)

Sphere

Popcorn

Star

77
110
140
65
89
145
70
100
139


(%
)
5
8
8
5
9
17
7
10
8

Ltip
(nm)

W1/2tip
(nm)

DLS size
analysis
Dhydro

(nm)
(%)

N/A
N/A
N/A
5- 35
5-55
15-65
10-75
15– 90
20 - 145

N/A
N/A
N/A
10-40
10-50
15-62
5-25
10-30
20-67

84
122
155
80
110
170
105
160
250

11
14
19
16
18
21
38
24
30

Absorption
property
LSPR (nm)

538
550
575
600
633
665
550, 660, 895
550, 684, 920
550, 715,>950

By adjusting the volume of the Au-seeded IO NP solution, IO-Au NPs of different sizes
were synthesized. Figure 3.5(A, B) shows the TEM images and DLS data for the IO-Au NSPs
prepared by injecting 800, 400, or 100 µL of the Au-seeded IO NP solution into a 5 mL growth
solution. The particles were homogenously dispersed, with average diameter (∼100 NPs) of 77,
110, and 140 nm (Table 3.2). The HDs were 84, 122, and 155 nm, slightly larger than the sizes
determined by TEM due to the coating and hydration layers. The thickness of the Au shell is
difficult to estimate because of the anisotropy of the octahedral IO core. When we considered the
size along the diagonal direction of the IO core, we estimated the average thickness of the Au
shell for the three sizes of particles to be 14, 30, and 45 nm, respectively. Free IO NPs were not
found in any samples, indicating complete conversion of the Au-seeded IO NPs to core-shell
particles. In contrast, when the IO NPs were coated with low density Au seed, a significant
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amount of free IO NPs was found (Figure 3.4). The resultant particles were polydisperse,
probably due to the formation of some solid Au NPs. The EDS spectra of all three sizes of
particles revealed the presence of both Fe (Fe Kα1 = 6.4 keV) and Au (Au Mα1 = 2.1 keV and
Lα1 = 9.7 keV) (Figure 3.5C), which is in accord with the assumption of core-shell structures.
Not surprisingly, the intensity of Au peaks increased, and those of Fe peaks decreased with
increasing Au shell thickness. When a magnetic field was applied, the particles were slowly
isolated by the magnetic force, with a complete separation from the solution at 2.5 h for the 77
nm, 5 h for the 110 nm, and 8 h for the 140 nm NSPs (Figure 3.5D). This indicates that the
synthesized NPs were indeed core-shell particles instead of solid Au NPs. We would like to point
out that the elongated magnetic separation time does not indicate that the IO-Au core-shell NSPs
have weak magnetic properties. This is because the separation time is proportional to not only
the magnetic force on the NPs but also the mass of the NPs. The estimated mass of the 70, 110,
and 140 nm IO-Au core-shell NSPs is 32, 130, and 278 times larger than IO NPs, respectively.
Thus, it is not surprising that it takes hours to separate the IO-Au core-shell NSPs from the
solution due to the dramatic mass contribution from diamagnetic Au that has four times higher
density than IO.
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Figure 3.5. (A) TEM image of Au-seeded IO NPs with low density of Au seeds. (B) TEM
image of the resultant NPs using the Au-seeded IO NPs shown in (A). TEM image (C) and
absorption spectrum (D) of IO-Au NPs prepared by adding 1000 uL into a 5 mL growth for
making IO-Au NSPs. TEM image (E) and absorption spectrum (F) of IO-Au NPs prepared
by adding 600uL into a 5 mL growth solution for making IO-Au NSPs.
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It is worth mentioning that further increasing the amount of Au-seeded IO NPs did not
result in IO-Au core-shell NPs with thinner shells. When we added 1000 µL of Au-seeded IO
NPs into the growth solution, we found the sample was composed of Au-seeded IO NPs but with
larger seeds than the initially adsorbed Au seeds (Figure 3.4C). Unlike the initial Au seeded NPs,
these NPs are susceptible to aggregation during the drying process that is required for the sample
preparation for TEM imaging. The NPs had a broad absorption spectrum with a strong LSPR at
541 nm (Figure 3.4D). These results indicate that the amount of Au precursor is insufficient for
the formation of uniform core-shell structures with the injection of a high volume of Au-seeded
IO NPs (>800 µL).
3.3.4. Synthesis of IO-Au Core-Shell NPCs and NSTs. To synthesize anisotropic NPs, we
added a small amount of AgNO3 (60 µM final concentration) into the growth solution. A further
control on the concentration of AA led to particles with different morphologies. The appearance
of a blue color indicates the growth of the Au-seeded IO NPs that completes within 2 h. By
increasing the concentration of AA by a factor of 2.5 (1.6 mM final concentration), IO-Au NPs
with short and wide protrusions, which we referred to as popcorns, were produced (Figure 3.6A).
Because the protrusions were heterogeneous, it was difficult to precisely quantify the size of the
NPs. Thus, we have defined a base size in terms of the inner spherical IO-Au core (see
illustration in Figure 3.6A inset). By adjusting the volume of Au-seeded IO NPs, IO-Au NPCs
with different base sizes were synthesized. The injection of 800, 400, and 100 uL of Au-seeded
IO NPs led to NPCs with an average base size of 65, 89, and 145 nm, respectively. The
protrusions became larger when the particle’s size increased, up to 65 nm in length and 62 nm in
half widths for the 100 uL sample (Table 2.2).
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Figure 3.6. Characterizations of IO-Au core-shell NPCs of different sizes. (A) TEM
images of 65 nm (left), 89 nm (middle), and 145 nm (right) IO-Au core-shell NSPs. Each
size was determined by averaging the diameter from ∼100 NPs in a spherical geometry
(see inset illustration) from the TEM images. (B) DLS plots. (C) EDS spectra. (D)
Optical images of IO-Au NPCs before and after magnetic separation.
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DLS measurement indicated that these NPs were well dispersed in water, with the
average HDs of 80, 110, and 170 nm for the three sized particles (Figure 3.6B). Similar to the
IO-Au NSPs, we confirmed the core-shell structures of the NPCs through EDS measurements
and magnetic separations. Figure 3.6C showed that both Fe and Au were detected by EDS.
Because free IO NPs were not found in the TEM images, the Fe peaks shown in Figure 3.6C
must be coming from the IO core in the IO-Au core-shell particles. The particles were
completely separated from the aqueous solution by a 12-tube magnet at 5 h for the 65 and 89 nm
particles and at 8 h for the 145 nm particles, which further confirmed their core-shell structures.
The IO-Au NSTs were synthesized using the same concentration of AA in the synthesis
of the spheres. Figure 3.7A shows the TEM images of IO-Au NSTs prepared via the addition of
350, 250, or 100 µL of Au-seeded IO NP solutions. The average base sizes of these NPs were 70,
100, and 139 nm. Each particle had multiple tips of different lengths. The tips were markedly
longer and thinner than the protrusions of the NPCs. For the small stars with a base size of 70
nm, the lengths of the tips ranged from 10 to 75 nm (Table 2.2). The lengths of the tips increased
with the base size of the NPs. Tips as long as 145 nm were observed for the large stars. DLS
characterization showed that the 70, 100, and 139 nm NSTs had average HD of 105, 160, and
195 nm, respectively (Figure 3.7B). By tuning the Au shell thickness, we have made the IO-Au
NSTs with an overall size smaller than 100 nm, which has not been achieved previously.
Additionally, the IO cores in these NSTs have large size, ∼4 times larger than those in previous
studies. Particles with larger IO core offer stronger magnetic properties as the magnetic
properties increase with the particle’s size.149, 214 As for the IO-Au NSPs and NPCs, the EDS
spectra of the NSTs showed presence of both Fe and Au peaks for each sample, confirming the
core-shell structure (Figure 3.7C). Magnetic separations were achieved using the Qiagen 12-tube
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magnets, leaving clear liquid solutions for all three sizes of particles (Figure 3.7D). This further
confirmed that the IO-Au NSTs were core-shell NPs rather than self-nucleated Au NPs.
Compared to the NSPs and NPCs, we found that the relative amount of Au precursor per
particle required to form uniform core-shell stars was significantly higher. Increasing the volume
of Au-seeded IO NP solution to 500 µL or more failed to produce NSTs, but up to 800 µL of Auseeded IO NP solution could be used to make core-shell spheres or popcorns. Figure 3.4E-F
shows the TEM image and absorption spectrum of the particles prepared by injecting 600 µL of
Au-seeded IO NPs into the growth solution. It is evident that the growth of the Au shell was
incomplete, and more Au precursor was needed to complete the growth process. These particles
had a LSPR peak around 630 nm and a shoulder peak around 910 nm, possibly resulting from
assembled Au seeds on the IO NPs.
3.3.5. Mechanisms of the Shape-Controlled Synthesis. Previous studies on Si-Au core-shell
NPs showed that the growth process begins with the growth of the adsorbed Au seeds into larger
seeds followed by coalescence on the core surface and, finally, the formation of a continuous
metallic shell.139 This is believed to be the general growth process for the seed-mediated method
in the preparation of metal nanoshells. For the formation of a star-shaped Au shell, the studies by
Wei and coauthors have implied that Au deposition at twinned boundaries with net growth in the
(111) direction is the dominate growth mechanism.151 To further understand the mechanism of
the shape-controlled synthesis using our system, we first followed the growth process of the
core-shell NSPs, NPCs, and NSTs with TEM imaging (Figure 3.8).
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Figure 3.7. Characterizations of IO-Au core-shell NSTs of different sizes. (A) TEM
images of 70 nm (left), 100 nm (middle), and 139 nm (right) IO-Au core-shell NSPs. Each
size was determined by averaging the diameter from ∼100 NPs in a spherical geometry
(see inset illustration) from the TEM images. (B) DLS plots. (C) EDS spectra. (D) Optical
images of IO-Au NSTs before and after magnetic separation.
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We found that the NSPs grew at a much faster rate than either the NPCs or NSTs. At 5
min, the Au seeds already entered the coalescence step, while no visible changes were observed
for NPCs and NSTs. At 20 min, a continuous Au shell has formed for the NSPs, while the NPCs
and NSTs were still in the coalescence step. After 20 min, the NSPs continued to grow into
larger particles and the NPCs, and NSTs showed similar growth rates. The differences in the
morphology of the particles were found at 30 min after seed injection. While the Au surface of
the NPCs has become rough with short and wide protrusions, thin spikes have developed on the
NSTs. This step occurred following the coalescence of the Au seeds. These spikes grew to form
the sharp tip of the NSTs during subsequent growth. In the HRTEM images we found the typical
(111) planes for Au on NSPs, the protrusions on NPCs, and the tips on NSTs. A twin boundary
was observed in the tip of NSTs, which was marked by the yellow line in the lower right image
of Figure 3.8.
As described in the previous sections, the growth of the Au seeded IO NPs into different
geometries is controlled by adjusting the AgNO3 and AA concentrations. Although the formation
of core-shell NSPs does not require the presence of AgNO3, it is required for the formation of
NPCs or NSTs. AgNO3 has been widely used to assist in the preparation of Au nanorods and
other anisotropic metal NPs.139, 215, 216 It has also been used to form spiky Au nanoshells from a
Ag- seeded polymer template.217, 218 A proposed model to explain the role of Ag+ in the synthesis
of these anisotropic NPs is based on silver underpotential deposition (UPD) and the reduction of
Ag+ to Ag0 on a metal substrate with a surface potential less than the standard reduction
potential.219 Thus, Ag+ ions are reduced and deposited onto the surfaces of Au seeds in the
presence of reducing agent. This may explain the slower growth rate for Au NPCs and NSTs
compared with the NSPs. To induce anisotropic growth, Ag deposition must occur at different
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rates on different crystal facets. To better understand the effects of Ag deposition for the particle
growth, we calculated the adsorption energy of an Ag atom on Au (100), (110), and (111)
surfaces using the first-principles density functional theory method (Figure 3.9A-C).
We found that the adsorption energy (the energy gain from adsorption) of Ag is highest
on the (110) surface, with an energy gain of 3.0 eV/atom. This is followed by the (100) surface,
where the adsorption energy is 2.7 eV. The adsorption energy of Ag is lowest on the (111)
surface, which is 2.2 eV/atom. The results from first-principles calculations are in agreement
with previous empirical calculations of reduction potential of Ag+ to Ag0 using the embedded
atom method (EAM), which shows that the reduction potential of Ag+ to Ag0 is higher on (110)
faces, followed by the (100) surface and (111) faces.220,221 Thus, Ag deposition is
correspondingly faster on the (110) facet, followed by (100) and (111) surfaces. With sufficient
Ag+ in the solution, Ag covers the (110) and (100) surfaces of Au seeds, blocking the adsorption
of Au on these faces. This blocking effect leaves only the (111) surface for Au growth, which
leads to anisotropic growth of the Au.
To fully understand the anisotropic growth of Au into a specific shape, we first took a
close look at the crystal structure of the tip of the Au NSTs. Figure 3.9D shows the proposed
structure of the tip, which is composed by two of the {111 planes, marked as (1 1 1) and (1 11). The tip extends toward the (1 1 0) direction. Figure 3.9E shows the HRTEM image of the tip,
where the (1 1 1) and (1 1-1) terminating planes are marked. According to our analysis, this
image corresponds to a side view of the tip when it is observed along the (1-1 0) direction. The
inset of Figure 3.9E is an enlarged view of the lattice at the interior of the tip, showing the
positions of each Au atom. Figure 3.9F shows the positions of atoms according to the proposed
model in Figure 3.9D when they were viewed along the (1-1 0) direction. It agrees well with the
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HRTEM image in Figure 3.9E, which confirms the proposed model in Figure 3.9D. As
mentioned above, when AgNO3 is absent, the final form of the Au NP is spherical. This is
because all the {100}, {110}, and {111} surfaces on a Au seed are available for Au deposition,
as shown in Figure 3.9G, leading to a nearly isotropic growth of the Au shell. On the other hand,
when AgNO3 is present, Ag will block the {110} and {100} surfaces of the Au seed, leaving the
{111} surfaces for Au deposition.
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Figure 3.8. Monitoring the growth process of IO-Au core-shell NPs in different shapes by TEM
imaging at different time after the injection of Au seeded IO NPs into the growth solution. The
yellow line in the HRTEM image for the star shows twinned defect. The same image in the top
row is used for all shapes to indicate that the same sample of Au-seeded IO NPs was used during
the synthesis.

The growth of the NPs into popcorns or stars is a kinetic control on the Au deposition.
This is achieved by controlling the concentration of AA that controls the reduction rate of Au+ to
Au0. As shown in Figure 3.9H, when the reduction of Au+ is fast, the Au deposition happens at
the entire (111) facet, leading to the growth of Au island along the (111) direction. Such a
mechanism is confirmed by the HRTEM image of the tip of the NPC, which shows that the tip of
the NPC grows along the {111} direction. As illustrated in Figure 3.9H, the growth of the tip can
happen along different {111} directions, such as (1 1 1) and (1 1-1), which lead to a popcorn
structure for the IO-Au core-shell NPs. On the other hand, when the reduction of Au+ to Au0 is
slow, the deposition of Au happens mainly at the ridge formed by two {111} planes, for
example, the (1 1 1) and (1 1-1) planes in Figure 3.9I. This is because the Au atoms at the ridge
are more undercoordinated than the atoms at the center of the facet, which makes them bind the
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Figure 3.9. Computational studies on growth mechanism. (A) The adsorption of Ag on the
Au(100) surface. (B) The adsorption of Ag on the Au(110) surface. (C) The adsorption of Ag on
the Au(111) surface. (D) Schematic of the proposed geometry of the tip of the nanostar. (E)
HRTEM image of a tip of the nanostar. The inset shows an enlarged view of the lattice, where
the position of each atom is visible. (F) The positions of atoms according to the proposed model
in (D), which is viewed from the [1-1 0] direction. (G) The growth mechanism of a Au
nanosphere. (H) The growth mechanism of a Au nanopopcorn. (I) The growth mechanism of a
tip of a Au nanostar. The twin boundary, which corresponds to the yellow line in the lower right
of Figure 3.8, is marked in dark blue color.
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adsorbed Au atoms more strongly. Also, the electrical field is stronger at the ridge than at the
center of the facet due to the larger curvature at the ridge, making the reduction of Au+ faster at
the ridge. The growth of Au on the ridge can be viewed as cohesive growth along two {111}
directions, as shown in Figure 3.9I. Such cohesive growth from two planes can lead to the
formation of a twin boundary along the (110) direction, shown as the dark blue plane in Figure
3.9I and the yellow line in the HRTEM in the lower right panel of Figure 3.8.
3.3.6.

Magnetic Properties of IO-Au Core-shell NSPs, NPCs, and NSTs. From the

magnetic separation experiments mentioned above, it can be seen that the IO-Au core- shell
NPs preserved the magnetic properties of the core. We additionally examined the temperature
dependence of the magnetization of IO-Au core-shell NSPs, NPCs, and NSTs. The results
showed that all these NPs (around 100 nm in the base size) had almost identical temperature
dependence (Figure 3.10A). At room temperature (300 K), they exhibited similar
ferromagnetic properties (Figure 3.10B) as the ferromagnetic IO core, which were indicated
by the hysteresis loops under low field (Figure 3.10B, inset). At low temperatures (10 K), the
field dependence of the magnetization of the particles showed both the ferromagnetic and
paramagnetic contributions (Figure 3.10C), consistent with the dramatic increase of the
temperature dependence of the magnetization at low temperature. Since the IO core was
ferromagnetic, the paramagnetic responses might originate from the Au shell. To further
demonstrate the paramagnetic behavior of the Au shell, we measured the M-T and M-H
curves of IO-Au NPs of three sizes of particles using the NPCs as a model system (Figure
3.10D-F). The results showed that the Au shell does not affect the ferromagnetic behavior at
300 K. However, the IO-Au NPs with thicker Au shell showed higher paramagnetic
contribution than those with thinner shell at 10 K.
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Figure 3.10. Comparison of the magnetic properties of IO-Au core-shell NPs by shape and size.
(A) Magnetization as a function of temperature for IO-Au NSPs, NPCs, and NSTs.
Magnetization as a function of applied field for NSPs, NPCs, and NSTs around 100 nm at 300 K
(B) and 10 K (C). (D) Magnetization as a function of temperature for IO-Au NPCs of three
different sizes. Magnetization as a function of applied field for IO-Au NPCs of three different
sizes at 300 K (E) and 10 K (F). The insets in (B), (C), (E), and (F) show the hysteresis loops
under low magnetic field.
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The hysteresis loops at 10 K (insets in Figure 3.10C, F) are larger than those at 300 K
(insets in Figure 3.10B, E) due to their higher retentivity at low temperature. It is well-known
that Au is a diamagnetic material in the bulk state. At the nanoscale, positive magnetization has
been reported in particles smaller than 5 nm.222 For the magnetic-plasmonic core-shell
nanostructure system, it has been widely studied and observed that the NPs exhibit the same
magnetic (superparamagnetic or ferromagnetic) behavior as the core at room temperature,197, 181,
117,196, 110, 223

similar to what we have observed in our particles. At low temperature, several

studies have shown that the NPs follow the ferromagnetic properties of the core.224-229 In our
studies, however, we have observed the paramagnetic properties of the IO-Au core-shell
nanosystem at low temperature. It has been recognized that the magnetic material could spin
polarize the Au conduction electrons at the IO-Au interface and thus result in magnetization of
the surrounding nonmagnetic Au.222 However, this does not provide an explanation for the
increased paramagnetic properties with increasing Au shell thickness. We therefore believe that
the external Au surface plays an important role. Research has shown that charge transfer between
a thiol ligand and a Au surface exists and is ascribed as a major reason for the observed
ferromagnetic properties of thiolated Au NPs.230 In our system, CTAB is the capping agent. It
has been suggested that CTAB binds to Au via Br- and is counterbalanced by CTA+ in a bilayer
structure.231-233 This suggests that charge transfer between Br- and Au may occur, which would
enhance the electron mobility and thus the surface-induced magnetism of Au.
Addition of a Au shell onto IO NPs generally leads to a dramatic reduction of the
amplitude of the magnetization of IO NPs due to the mass contribution of the diamagnetic Au
that has 4 times higher density than Au. For example, in the studies by Halas and co-workers,234
coating tetracubic IO NPs with a 10.9 nm Au shell decreased Ms from 15 emu/g to 0.5 emu/g.
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To examine the effect of Au coating on the amplitude of the magnetization of IO NPs in our IOAu core-shell system, we used the 145 nm IO-Au core-shell NPCs as the model and
quantitatively measured the M-0H curve at 300 K. The Ms of the IO-Au core-shell NPCs is 0.20
emu/g. To explain whether Au coating had an adverse effect, we estimated the theoretical Ms of
the 145 nm IO-Au core-shell NPs based on the Ms of IO NPs, densities of IO and Au, and the
dimension of the core-shell NPCs (Table 2.2). We took an assumption that each popcorn is
composed of six protrusions, with each protrusion modeled as a conical Au tip with length of 20
nm and width of 30 nm. Based on these parameters, the calculated Ms of the IO-Au core-shell
NPCs is 0.28 emu/g, which is comparable to the experimental value. It is also worth mentioning
that we did not consider the mass contribution from the diamagnetic PEI that was coated onto
Au-seeded IO NPs before the growth of the Au shell and the CTAB capping molecules on the
Au surface. Further, some popcorns have more than six protrusions and have larger protrusions.
These additional factors will further reduce the theoretical Ms value. Thus, the addition of a Au
shell did not play a significant adverse effect on the magnetic properties of the IO core. The
reduction of the magnetization after Au coating is mainly due to the dramatic increase of the
mass of the core-shell NPs (>300 times for the 145 nm IO-Au core-shell NPCs compared to the
IO NPs) by the Au shell.
3.3.7. Optical Properties of IO-Au Core-Shell NSPs, NPCs, and NSTs. The IO-Au NSPs
exhibited LSPR bands in the visible region from 530 to 600 nm depending on the size of the
particles (Figure 3.11A). Increasing the size from 77 to 140 nm by increasing Au shell thickness
led to a red shift of the LSPR from 538 to 575 nm. In our previous computational study using
extended Mie theory, we found a blue shift of the LSPR when the thickness of the Au shell was
increased from 2 to 17.5 nm but a red shift with further increase of Au shell thickness on a 15 nm
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diameter IO core. In this study, the shell thicknesses were more than 14 nm, and thus, it was not
surprising that we observed red-shifted LSPR for particles with increased Au shell thicknesses.
The absorption coefficients of these NPs have yet to be determined. However, it is
significant to note that the absorption spectra were obtained from the as-prepared particle
solutions. Thus, the particle concentration depends on the amount of Au-seeded NPs injected
into the growth solution. Assuming that all the Au-seeded NPs were converted to core-shell
particles, we estimated from the measured LSPR intensities that the absorption coefficients of the
110 and 140 nm IO-Au NSPs are 2.5 and 9 times higher than that of the 77 nm IO-Au NSPs due
to the increase on the size of the particles. The measured UV-vis spectra of the NPCs are shown
in Figure 3.11B. The spectra show a LSPR peak at 600, 633, and 665 nm for the NPCs with base
sizes of 65, 89, and 145 nm, respectively. Note that the overall sizes of the particles are slightly
larger due to the protrusions on the surface of Au. Similar to the NSPs, an increase in the Au
shell thickness led to red-shifted LSPR bands. Compared to the NSPs of similar size, the LSPR
peaks of the NPCs were shifted to longer wavelengths, and the bands were broadened, owing to
the anisotropic Au shell of the NPCs. Different from the NSPs and NPCs, the NSTs show three
distinct peaks around 550 nm (weak), 700 nm (strong), and over 850 nm (strong) (Figure 3.11C).
While the plasmon resonance in the visible region is insensitive to the particle size, it red shifts
for the two peaks in the NIR region when the size is increased. When the base size of the
particles was increased from 70 to 100 and 139 nm, the plasmon resonance for the middle peak
was shifted from 660 to 684 and 715 nm. The plasmon resonance for the red-most peak was
shifted to 920 nm and to a position over 950 nm that is out of the detection range of our
spectrometer.
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Figure 3.2. Absorption spectra of IO-Au core-shell NSPs (A), NPCs (B), and NSTs (C) of
different sizes. The sizes labeled in the graphs are the base size of the particles that do not
include the protrusions in popcorns and tips in the stars.
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It should also be noted that the NSTs exhibit most red-shifted plasmon resonance
compared to the NSPs and NPCs due to the elongated tip structure of the stars. Considering the
differences in the concentrations of NPs used in the absorption measurements, we have estimated
that the ratio of the absorption coefficients of the 65, 89, and 145 nm NPCs is roughly 1:1.6:8.3,
and that of 70, 100, and 139 nm NSTs is 1:1.4:2.8. Due to the anisotropic structures, both IO-Au
NPCs and NSTs have great potential for SERS-based applications. The SERS activities also
largely depend on the excitation laser wavelength. Due to their differences in the optical
properties, the NPCs are expected to give strong SERS signals at 632 nm excitation, while the
NSTs are expected to give strong SERS signals at 785 nm.
To gain a better understanding of the effects of size and morphology on the optical
properties of IO-Au core-shell NPs, we have used the DDA method to calculate the extinction
spectra of IO-Au core-shell NPs of spheres, popcorns, and stars with varied shell thickness
considering the particle’s dimension given by TEM. Figure 3.12A shows the calculated
extinction spectra for three sizes of IO-Au NSPs with octahedral cores (edge length a = 35 nm).
With increasing sizes from 70 to 100 and 140 nm (due to increasing Au shell thickness), the peak
width broadens, and the peak maximum red shifts from 563 to 576 and 626 nm. The observed
trends for the calculated spectra match favorably with the experimental results shown in Figure
3.11A.
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A

B

C

Figure 3.3. Calculated extinction spectra for the three sizes (D = 70, 100, and 140 nm) of IO-Au
core-shell NPs with octahedral IO cores (edge length a = 35 nm). (A) IO-Au core-shell NSPs (no
tips). (B) IO-Au core-shell NPCs modeled by adding six conical tips with L = 20 nm and w = 30
nm. (C) IO-Au core-shell NSTs modeled by adding six conical tips with L = 40 nm and w = 30
nm. The insets are the 100 nm particle models shown to scale.
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For the NPCs and NSTs, we have chosen to investigate the effects of adding tips to the
three sizes of NSPs on their respective extinction spectra as it is difficult to represent the
synthesized popcorn or star samples in a single particle calculation. Six conical tips with lengths
(L) of 20 nm for NPCs and 40 nm for NSTs were added to the surfaces of the IO-Au NSPs along
the x, y, and z axis. The width (w) of the tips for both NPCs and NSTs is 30 nm. Figure 3.12B
and 2.12C shows the calculated extinction spectra for NPCs and NSTs with the base sizes of 70,
100, and 140 nm. The results show that the addition of tips results in extinction spectra with
multiple LSPR peaks. When the tip is short (the popcorn), the multiple peaks are not well
resolved, resulting in a spectrum consisting of a broad peak. Comparing to the IO-Au NSPs
shown in Figure 3.12A, the predominant LSPR peak for the NPCs is red-shifted to over 600 nm
(630, 632, and 657 nm, respectively). The original peak in the NSP spectrum appears as a
shoulder around 550 nm. These spectra agree reasonably with experimental spectra shown in
Figure 3.11. Increasing the length of the tips to 40 nm (the star) results in the appearance of
additional LSPR peaks. As we can see in Figure 3.12C, the NSTs are characterized by two
distinct peaks at 740 and 870 nm and two weaker peaks around 550 and 640 nm. Previous
computational studies by Hao et al. using the finite-difference time-domain (FDTD) method
showed similar spectral features for solid Au NSTs.235 They explained that the multiple plasmon
resonances result from the hybridization of the core and tip plasmons. We speculate that the
peaks shown in Figure 3.12C are likely a similar result from the hybridization of plasmons
associated with the IO-Au spherical core and the Au tips. The first peak around 550 nm could be
mainly due to the plasmon resonance of the IO-Au NSP core but with a finite contribution from
the tip plasmons. The peaks corresponding to additional LSPR modes at 640, 740, and 870 nm
are likely the result of plasmonic coupling of the core and tips.
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By increasing the base sphere size of the NSTs without changing the tip dimensions, we
observe an increase in the intensities of the first two LSPR peaks within 700 nm but a reduction
in intensities of the peaks at longer wavelength (∼740 and ∼870 nm), with only small shifts of
the peak positions. This feature is also observed in experimental spectra for NSTs shown in
Figure 3.12C. The correlation between the DDA calculated and the experimental NST spectra is
not as strong as for the NSP and NPC spectra. This is not surprising as the experimental spectra
have been collected from a bulk sample of IO-Au NSTs with varied number and length of tips
and the calculated spectra from a single particle with fixed number and length of the tips. We
envision that the number and length of the Au tips will be the major players in further tuning the
optical properties of the IO-Au NSTs. The exact correlation between observed LSPR peaks and
the NST properties of tip length, tip width, and number of tips will be investigated in detail in a
future study
3.4. CONCLUSIONS.
In conclusion, we have synthesized monodisperse IO-Au core-shell NPs in sphere,
popcorn, and star shapes with tunable Au shell thickness, leading to compact magnetic- plasmonic
NPs less than 100 nm in each shape. We have shown that the shape was evolved after coalescence
of Au seeds on the IO core. Deposition of silver atoms onto the Au surface led to anisotropic NPs
due to the difference in the adsorption energy of Ag on different Au lattice planes. The growth of
the NPs into popcorns or stars is a kinetic control on the deposition of newly formed Au atoms
through controlling the reduction speed of Au precursors. This provides microscopic insights into
the engineering of advanced plasmonic-based nanomaterials. The IO-Au core-shell NPs exhibit
strong magnetic properties and tunable optical properties depending on the shape. The IO-Au
NPCs and NSTs showed red-shifted localized surface plasmon resonance compared with the NSPs,
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with the nanostars giving strong plasmon resonance in the near-infrared region. The NSTs showed
distinct multiple LSPR modes due to the elongated tip structure on the IO-Au spherical core. These
highly integrated bifunctional nanostructures will have significant applications for biomedical and
materials research.
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CHAPTER 4: Molecular Detection and Analysis of Exosomes Using Surface-Enhanced
Raman Scattering Gold Nanorods and a Miniaturized Device

4.1.

Introduction

Extracellular vesicles, especially exosomes, are receiving increasing interest as a resource
of biomarkers in medicine.236 Although they were discovered in the early 1980’s, exosomes have
only recently moved into intense investigations regarding their biogenesis, composition, and
functions.237-240 It is now believed that exosomes are 30-200 nm membrane-bound vesicles
derived from multivesicular bodies and released into the extracellular environment by many cell
types.241-243 They carry molecular constituents of their originating cells including proteins,
nucleic acids, and lipids and represent an important mode of intercellular communication by
horizontal transfer of their molecular contents between cells244-249
Growing evidence suggests that cancer-derived exosomes can transfer oncogenic activity
and regulate angiogenesis, immunity, and metastasis to promote tumorigenesis and
progression.250-254 For example, Peinado et al. demonstrated that exosomes from highly
metastatic melanoma cells educated bone marrow progenitor cells toward a pro- metastatic
phenotype via horizontal transfer of exosomal MET.255 Zhou et al. showed that exosomemediated transfer of miR-105 in metastatic breast cancer cells efficiently destroyed vascular
endothelial barriers to promote metastasis.256 Exosomes have also been found in various body
fluids such as blood, urine, saliva, and cerebrospinal fluid.257-260 Thus, exosomes are a promising
resource of cancer biomarkers to noninvasively screen for cancer, assess cancer progression, and
monitor treatment responses261-269
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Despite their diagnostic and therapeutic potential, the clinical use of exosomes as cancer
biomarkers is, however, still very limited. One of the major challenges is molecular detection
and analysis due to their small size and complex biological environment. To ensure analytical
accuracy, exosomes usually need to be isolated and purified from cell culture supernatant or
plasma before analysis. Classical methods for exosome isolation are differential centrifugation,
filtration, immunomagnetic separations, and microfluidics.270-273 Differential centrifugation
consists of a series of low, high and ultrahigh speed centrifugations to separate exosomes from
cell debris, larger microvesicles, and proteins based on size and density. It is the gold-standard
method to purify exosomes. After purification, exosomes have been commonly analyzed for
protein compositions using western blot, enzyme-linked immunosorbent assays (ELISA), and
mass spectrometry.274-278 These traditional approaches have greatly helped understand exosome
biology, but they are impractical for longitudinal studies and clinical use because they are time
consuming and labor intensive. Technologies for exosome detection and analysis have been
greatly advanced in past few years.276,279 For example, the nPLEX assay has improved detection
sensitivity as high as 1000-fold compared to ELISA.280 New flow cytometry instrumentation can
analyze individual exosomes down to 70-80 nm.281 In these techniques, exosomes are detected
based on fluorescence,281-291 surface plasmon resonance (SPR),280, 292-294 light scattering plasmon
resonance,295 nuclear magnetic resonance,296 electrochemical297-302 and mechanical
approaches.303
Here we report a new method for exosome detection and protein profiling using surface
enhanced Raman scattering (SERS) nanotags in combination with a miniaturized capture
platform. SERS is the enhancement of Raman signals from small molecules that are proximal to
a metal surface via electromagnetic and chemical mechanisms.304 It is an ultrasensitive
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vibrational spectroscopic technique, with Raman enhancements as high as 1015 for small
molecules, such as organic dyes, on plasmonic nanoparticle surfaces.305, 306 The SERS effect has
been previously used to probe exosome composition,307-310 but here we report the use of SERS
nanotags for exosome detection and analysis. SERS nanotags, which are plasmonic nanoparticles
carrying abundant Raman reporters, such as organic dyes, can provide highly sensitive and
specific detection by controlling the surface chemistry, size, and structure of the plasmonic
nanoparticles, and the surface density of the Raman reporters.311 Compared to the classic
fluorescence method, SERS gives fingerprinting signals that distinguish interferences from a
biological background.230 The SERS spectrum only requires a simple baseline correction using a
multi segment polynomial fitting to subtract SERS background (broad continuum emission).
This baseline correction can be incorporated in the signal correction software and thus the as
acquired spectrum does not need further signal separation processing for quantitative analysis. In
addition, signal acquisition is extremely fast when SERS nanotags are used (1 s or faster per
spectrum) due to the high sensitivity of SERS nanotags. Due to these attributes, SERS nanotags
have emerged as a popular class of biological labels and have been well used for cancer
detection, including biomarker detection in body fluids.304, 311-319 Here we report the first
application of SERS nanotags for exosome detection and analysis. We used small gold nanorods
(AuNRs) as the SERS substrate. The AuNRs are sufficiently small (~35 nm in the longitudinal
dimension) in comparison with the small exosomes. The anisotropic rod structure promotes
SERS effects due to the high electromagnetic fields at the ends of the rods64 We made use of 3D
printing technology to improve analytical efficiency. 3D printers are cheap, portable, and easyto-use. They are accessible to large populations, especially in resource-limited environments.
Using a 3D-printed array template, we made an antibody array to capture exosomes in a target-
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specific manner on Au-coated standard glass microscopy slides. Combining the advantages of
SERS nanotags and 3-D printing technology, this simple and low-cost assay offers dozens of test
sites on a single palm sized chip, provides results within 2 h, and has a microliter sample
requirement at femtomolar concentrations. Due to its simplicity, high efficiency, and high
sensitivity, this assay has great potential for clinical applications for biomarker discovery and
understanding of the role of exosomes in cancer development
4.2.

Materials and Methods

4.2.1 Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
specified. Antibodies were purchased from Biolegend (San Diego, CA). QSY21 carboxylic acidSuccinimidyl ester was purchased from Thermo Fisher Scientific. PE-labeled antibodies were
purchased from Miltenyi Biotec (Auburn, CA). All cell lines were purchased from ATCC
(Manassas, VA). Cell culture media were purchased from VWR (Radnor, PA) and fetal bovine
serum (FBS) was purchased from Fisher Scientific (Waltham, MA).
4.2.2.

Synthesis of gold nanorods (AuNRs)
Small gold nanorods (AuNRs) were synthesized by modifying the classic seed mediated

growth method.320 This method involves two steps: preparation of Au seeds and growth of Au
seeds into AuNRs in a growth solution. To make the Au seed solution, 0.5 mL of 1 mM
chloroauric acid (HAuCl4) was added to 1.5 mL of 0.2 M cetyltrimethylammonium bromide
(CTAB) solution with constant stirring. 120 µL of 10 mM ice-cold sodium borohydride (NaBH4)
was quickly injected and the solution was stirred for 3 min to form the Au seed solution. The Au
seed solution was kept undisturbed for 3 h in a 25 °C water bath before its use. In a different
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glass vial, 5 mL of 1 mM HAuCl4 was added to 5 mL of 0.2 M CTAB solution followed by
addition of 125 µL of 4 mM silver nitrate (AgNO3). After mixing by stirring, 12 µL of Au seed
solution was quickly injected into the solution and left undisturbed for 10 min to form small
AuNRs. The solution was centrifuged at 16,000 × g for 10 min and the AuNR pellet was
resuspended in ultrapure water for further use.
4.2.3.

Preparation of SERS AuNRs
One hundred microliter of 100 µM QSY21 carboxylic acid (hydrolyzed from QSY21

carboxylic acid-succinimidyl ester) aqueous solution was added to 1 mL of 2 nM AuNRs and the
mixture was stirred for 15 min at RT to allow adsorption of the dye onto the AuNRs. After
purification by centrifugation (16,000 × g, 10 min), the QSY21 carboxylic acid-adsorbed AuNRs
were resuspended in phosphate buffer solution (PBS) to make 1 nM solution. The solution was
aged at room temperature (RT) for 2 h before use.
4.2.4. Au thin film deposition on microscopy glass slides
A standard microscopy glass slide (75 × 25 × 1 mm) was coated with a 10 nm thick Au
film by the magnetron sputtering technique using an ORIONAJA system from a 99.99% pure
Au target. The deposition of the Au layer was performed on a 4 nm titanium layer previously
deposited from a 99.99% pure titanium target on the glass slide. The slide-target distance was
kept at 15 cm during the process. The film thickness was controlled by an INFICON SQM-160
quartz crystal monitor/controller equipment. The rotating substrate holder was kept at 80 rpm.
The films were grown in an atmosphere of argon at 3.0 mTorr and a gas flow of 15 sccm, with
the DC power supply set to 100 W and the pressure before inserting the argon was 4.0×10-8
Torr. The whole process took 4 h.
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4.2.5. Fabrication of array template

Plastic (polylactic acid) array templates with specified well size and inter-well distance were
fabricated using a MakerBot Replicator PC 3-D printer. The template was attached to a rubber
array via a layer of glue composed of 60% silicone and 40% mineral spirit. This rubber array was
made from a 1.6 mm thick rubber sheet with the same dimensions as the template via puncture.
The assembled plastic and rubber arrays were used as a template array to make an antibody array
on the Au-coated glass slides.
4.2.6. Fabrication of the antibody-based capture array
The template array was attached onto the surface of the Au-coated glass slide using 3/4"
wide heavy-duty binder clips. 15 µL of 50 μg/mL target-specific antibody-linked polyethylene
glycol thiols (HS-PEG-Ab) in PBS was added into the wells and incubated for 5 h at RT. The
HS-PEG-Ab was prepared in advance by reacting antibodies with thiolpolyethylene glycol- Nhydroxysuccinimide esters (HS-PEG-NHS 5000,1:100) at 4 °C overnight. The free HS-PEGNHS was separated by membrane filtration with a 10 kD Nanosep filter (PALL Life Sciences).
The antibody-treated wells were washed three times with phosphate buffer solution-tween
(PBST) (100 mL PBS + 0.5 mL Tween 20 (0.5%)) to get rid of unbound proteins. Then, 15 µL
of 0.1 mM 11-mercaptoundecyl tetra (ethylene glycol) (MU-TEG) was added into the wells and
incubated for 30 min at RT to saturate the Au surface. The antibody functionalized wells were
washed three times with PBST and stored at 4 °C for further use. Isotype IgG was used as the
negative control.
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4.2.7.

Isolation and characterization of exosomes in culture media
Human breast cancer cells MDA-MB-231(MM231), MDA-MB-468 (MM468), and

SKBR3 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with high glucose
(MM231 and MM468) RPMI 1640 medium (SKBR3) with 10% fetal bovine serum at 37 °C
under 5% CO2. Human breast normal cells MCF12A (immortalized) were cultured in Dulbecco's
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) medium with 5% fetal horse
serum, 1% Pen/Strep (100×), 0.5 mg/mL hydrocortisone, 10μg/mL bovine insulin, 100 ng/mL
cholera toxin, and 20 ng/mL epidermal growth factor (EGF). Cells were grown in conditioned
cell culture media (media + 10% exosome-free FBS) for 48 h. The exosome-free FBS was
obtained by separating exosomes from FBS with ultracentrifugation (100,000 ×g, 24 h).
To collect exosomes, the conditioned cell culture supernatant was collected and centrifuged at
430 × g at RT for 10 min. The supernatant was collected and centrifuged at 16,500 ×g at 4 °C for
30 min. The supernatant was collected and centrifuged at 100,000 × g at 4 °C for 70 min. After
removing the supernatant, the exosome pellet was resuspended in cold sterile PBS and
centrifuged again at 100,000 × g at 4 °C for 70 min. The exosome pellet was resuspended in cold
sterile PBS, filtered with a 0.2 μm PES filter (Agilent Technologies), and stored at - 80 °C until
use. The concentration and size distribution of exosomes were characterized using nanoparticle
tracking analysis (NTA) with a NanoSight LM10 microscope (Malvern Instruments, Inc).
4.2.8.

Isolation and characterization of exosomes in plasma samples
Plasma samples from six human epidermal growth factor receptor 2 (HER2) positive

breast cancer patients (stage III) and three healthy donors were purchased through the
XpressBank from Asterand Bioscience (Detroit, Michigan). The samples were collected in 2016
and 2017 and stored in liquid nitrogen (LN). The samples were available for research uses under
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IRB exemption through the BioSPOKE™ custom biospecimen procurement service. The
identity information of each subject was coded with a unique Donor Identification Number
(DIN) and we do not have access to the identifying information. To purify exosomes, the plasma
samples were diluted with sterile PBS and centrifuged at 16,500 × g for 30 min at 4 °C. The
supernatant was collected and centrifuged at 100,000 × g for 70 min at 4°C. The exosome pellet
was resuspended in cold sterile PBS and centrifuged again at 100,000 × g for 70 min at 4 °C. The
pellet was resuspended in cold sterile PBS, filtered with a 0.2 μm PES filter, and characterized
with NTA to determine the concentration and size distribution of exosomes. The exosomes were
stored at -80 °C until use. Exosomes from healthy donors were obtained from fresh whole blood
samples through Analytical Biological Science (Wilmington, DE). The whole blood samples
were centrifuged two times at 2,500 × g for 15 min at 4 °C. Plasma was collected as the
supernatant and processed further based on the above procedures to obtain exosomes.
4.2.9. Exosome binding, SERS detection, and fluorescence imaging
Fifteen microliters of 6.25×107/mL exosomes were added to the antibody-functionalized
Au array wells and incubated for 30 min at RT. After washing the wells three times with PBS,
15 µL of 1 nM SERS AuNRs was added and incubated for 30 min. After washing three times
with PBS, 15 µL of PBS was added and exosomes in the wells were detected with a TSI
ProRaman spectrometer (λ= 785 nm). The laser beam size at focus was 200 µm. Each spectrum
was collected with a laser power of 50 mW and acquisition time of 1 s. Baseline correction using
multi segment polynomial fitting was automatically performed by the signal acquisition software
(EZ Raman Reader v8.1.8) to subtract SERS background (broad continuum emission). The peak
at 1497 cm-1, which is the strongest among all the peaks of the QSY21 SERS spectrum, was
used as the representative peak for analysis. To account for variations from instrumentation
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response and batch-to-batch nanotag preparation, the spectrum of the SERS nanotag solution (0.1
nM) during each experiment was collected and the intensity of the 1497 cm-1 peak was
normalized to 2500 a.u., the typical value of a 0.1 nM nanotag solution. This gave a correction
factor for each nanotag to correct the signal intensity from exosomes labeled with that nanotag
during each experiment. The corrected intensity of the 1497 cm-1 peak was used for analysis. The
whole process from exosome binding to signal readout took ~2 h. To confirm the captured
exosomes, exosomes were labeled with 1 mM 3,3’-Dioctadecyloxacarbocyanine perchlorate
(DiO) in PBS for 15 min at RT. Exosomes were then washed with PBS and examined by a
fluorescence microscope (Olympus IX 71) with a Prior Lumen 200 illumination system. The
excitation and emission were 482/35 nm and 536/40 nm respectively.
4.2.10. Enzyme-linked immunosorbent assay (ELISA)
Fifty microliters of 6.25×108/mL exosomes were added into a 96-well polystyrene plate
(Corning Incorporated) and incubated at 4°C overnight. The wells were washed three times with
Dulbecco's phosphate buffered saline (DPBS) followed by incubation with 100 µL of blocking
solution (DPBS with 4% BSA) at RT for 2 h. After washing three times with DPBS, each well
was treated with the following solutions sequentially: 50 µL of 2.0 µg/mL target-specific
antibodies (2 h, RT), 50 µL of horseradish peroxidase (HRP)-conjugated anti-mouse IgG
antibody (ThermoFisher, 1:60 dilution in blocking solution; 1 h, RT), and 100 µL of 3,3,5,5tetramethylbenzidine solution (TMB, Sigma Aldrich; 30 min, RT). The wells were washed three
times with DBPS between steps. After the TMB incubation, 100 µL of 2 M sulfuric acid (H2SO4)
was added to stop the reaction. The optical density of each well was measured at 450 nm using a
BioTEK ELx800 absorbance microplate reader. Isotype IgG was used as the control.
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4.2.11. Statistical analysis
Statistical analysis was performed to compare the expression levels of target proteins
across different cell lines using analysis of variance (ANOVA) with post hoc Scheffe method.230
A p-value ≤ 0.01 was considered significantly different. The mean difference between different
groups was considered to be significant if the absolute value was greater than the minimum
significant difference derived from the Scheffe method. The marker difference between breast
cancer patients and healthy donors was evaluated from generalized estimation equations
(geepack v1.2-1 in R) to account for the measurement correlation within each individual. The
diagnostic value of identified markers in breast cancer patients was evaluated by receiver
operation characteristic (ROC) curve analysis using R packages.
4.3.

Results and Discussion
Figure 4.1A shows the schematic design of the Raman exosome assay. It contains three

major steps: (1) preparation of the antibody array, (2) labeling of the captured exosomes with
SERS AuNRs, (3) detection of exosomes with a portable Raman spectrometer. The antibody
array was fabricated on a Au-coated standard glass microscopy slide (75 × 25 × 1 mm) with the
assistance of a 3-D printed array template. Exosomes were captured on the Au slide via the
target-specific antibodies. To detect the captured exosomes, we made use of the surface
properties of exosomes and AuNRs. Exosomes are negatively charged (zeta potential around -10
mV) because of their lipid membrane. AuNRs are positively charged (zeta potential around +35
mV) because of the bilayer CTAB capping agent. The Raman reporter was incorporated in the
CTAB bilayer via hydrophobic interactions to give SERS signals for detection. Thus, we
hypothesized that captured exosomes via surface proteins could be detected with AuNRs via
SERS through electrostatic interactions between the AuNRs and exosomes (Figure 4.1B-C).
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A

B

C

Figure 4.1. Design of the Raman exosome assay. (A) Schematic overview of the Raman
exosome assay. A protein array was fabricated on a gold chip (75 × 25 × 1 mm) using a 3Dprinted template array. Exosomes were recognized and immobilized on the Au chip via the
target-specific proteins anchored on the surface of the chip. Immobilized exosomes were
recognized by surface enhanced Raman scattering small gold nanorods through electrostatic
interactions between cetyltrimethylammonium bromide on gold nanorods and lipid membrane on
exosomes. SERS signals were detected with a high-performance portable Raman spectrometer.
(B) Side view of the interactions of exosome lipid membrane and AuNR. (C) Top view of the
interactions of exosome lipid membrane and AuNR.
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AuNRs were synthesized using the well-established seed-mediated growth method. 320,155
To ensure efficient binding to the small exosomes, we synthesized small AuNRs by
controlling the growth time to ten minutes after seed injection. The AuNRs were 35 nm in length
and 12 nm in width on average, with localized surface plasmon resonance (LSPR) at 720 nm
(Figure 4.2A-B). It has been reported that AuNRs with such LSPR properties give stronger
SERS activities than those with LSPR at shorter or longer wavelengths due to the competitive
effect of SERS enhancement and extinction.321 We took advantage of the unique surface
chemistry of AuNRs for the preparation of SERS AuNRs. The as prepared Au NRs were
stabilized with positively charged CTAB in a bilayer structure.322 This bilayer of CTAB provides
a hydrophobic pocket for loading hydrophobic molecules such as organic dyes via hydrophobic
interactions (Figure 4.2C). Organic dye QSY21 was used as the Raman reporter because it is
non-fluorescent and gives fingerprinting signals. To load hydrophobic QSY21 onto aqueous
AuNRs, we used the amphiphilic form QSY21 carboxylic acid. The QSY21 carboxylic acid was
formed by hydrolyzing QSY21 carboxylic acid-succinimidyl ester in water. QSY21-coated
AuNRs were formed by mixing QSY21 carboxylic acid with AuNRs (5000:1) in water with
constant mixing for 15 min. Free Raman reporters were separated by centrifugation for 10 min at
12,000 x g.
We investigated the stability of the SERS AuNRs in PBS by monitoring their absorption
and SERS spectra with time after preparation (Figure 4.2D-E). Within the 5 h study time, we
found that the absorption intensity of the SERS AuNRs gradually decreased by 20% and SERS
signal intensity increased by 18% within the first 2 h. Then, the signals did not change within the
next 3 h. These results show that the SERS AuNRs are slightly aggregated within 2 h after
preparation but then they are stable for hours.
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Figure 4.2 Characterization of AuNRs and SERS AuNRs. (A) TEM image of AuNRs. (B)
Absorption spectrum of AuNRs. (C) Schematic of the preparation of SERS AuNRs using QSY21
as the Raman reporter. (D, E) Stability of CTAB/QSY21/AuNRs in PBS at different time after
preparation, which was monitored by absorption (D) and Raman (E) measurements. Absorption
in (D) was measured at the localized surface plasma resonance of AuNRs. SERS signal intensity
in (E) was measured at the 1496 cm-1 peak. (F) SERS signal intensity of QSY21-coated AuNRs
at different particle concentrations. (G) The SERS signal intensity of QSY21-coated AuNRs at
different AuNR concentrations. Data in (G) are presented as mean values from three replicated
experiments with standard deviation.
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For comparison, we investigated the stability of the AuNRs in PBS without QSY21. The
results showed that the absorption intensity of the AuNRs decreased by 7% within 2 h and then
was constant within the next few hours. The mechanism for this phenomenon remains to be
explored. But, it is not surprising that the SERS AuNRs are stable as CTAB is a known strong
capping agent. Based on the stability studies, we thus let the SERS AuNRs age for 2 h before
use. The labeling time was only 30 min and the Raman measurements were performed right after
labeling. Thus, during our sample processing and signal measurement, the SERS AuNRs were
stable and signals from exosomes were reliable. The SERS signals of QSY21-coated AuNRs
showed excellent linearity respective to the concentration of the AuNRs, with a correlation
coefficient of 0.98 (Figure 4.2F-G). Thus, the QSY21-coated AuNRs can be used for reliable and
quantitative detection and profiling.
The microscopy glass slide was coated with a 10 nm Au film to facilitate surface
chemical modification via high vacuum thin film deposition with an AJA deposition unit. The
Au film is optically transparent and thus allows for optical imaging. A photographic picture of
the Au-coated glass slide is shown in Figure 4.3A. To increase sample throughput, we separated
the Au slide into an array of wells using a 5 mm-thick 3D-printed plastic array template (Figure
4.3B). Suitable arrays should ensure (1) no leaking of the wells and (2) clean manual washing of
the samples in the wells. We printed and tested several arrays with variable well sizes and interwell distances. We found that the smallest size of the well was 2 mm in diameter and the
smallest distance between neighboring wells was 2 mm. Accordingly, a 17 × 5 array can be made
per template. This template provides 85 test sites per slide. Each well can hold a maximum of 15
µL solution.
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Figure 4.3. Characterization of the Au array for target-specific exosome capture and
detection. (A) A photograph of the Au-coated microscopy glass slide. (B) A photograph of
the Au array device formed using a 3-D printed template array. The Au array is 17 × 5,
with a well size of 2 mm and a gap of 2 mm. (C) Schematic of the chemical surface
modification of the Au surface with target-specific antibodies. (D) Size distribution of
MM231 exosomes characterized with NTA. (E, F) Evaluation of the specificity of the
Raman exosome assay by the average SERS spectra (n= 3) (E) and mean signal intensity of
the 1497 cm-1 peak (F) from different experiments (1-5). SERS AuNRs were added in
experiments 1 and 5. (G) Fluorescence image of MM231 exosomes captured with CD63
antibodies.
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The template was attached on top of the Au chip with a rubber interface array that
allowed tight sealing of the plastic array template to the Au chip so that the solution in each well
did not leak out. The Au surface of the wells was functionalized with target specific antibodies to
capture exosomes (Figure 4.3C). This was done by incubation with target specific HS-PEG-Ab
followed by saturation with hydrophilic MU-TEG. HS-PEG-Ab was prepared by reacting HSPEG-HS (MW 5000) with antibodies at 4°C overnight followed by purification with a 10 kD
Nanosep filter. The shorter MU-TEG was used to minimize nonspecific interactions of exosomes
and SERS AuNRs with the Au slide.
To examine the specificity of the chemically modified Au slide and the SERS AuNRs for
exosome capture and detection, we isolated and purified exosomes from the MM231 model
breast cancer cell line. Exosomes were isolated from conditioned culture supernatant using the
standard differential method. In this isolation method, cell debris was separated by low-speed
centrifugation (430 × g) and microvesicles by medium speed centrifugation (16,5000 × g).
Exosome pellet was collected after ultracentrifugation at 100,000 ×g. The exosomes were
characterized by NTA to determine their concentration and size distribution. The MM231
exosomes have sizes of 168 ± 49 nm (mean ± standard deviation (SD)) (Figure 4.3D). Figure
4.3E shows SERS spectra of CD63-targeted exosomes compared with several controls. The
isotype IgG control gave a signal intensity of 48 a.u. at 1497 cm-1. When anti-CD63 antibodies
were used, the signal intensity increased to 1582 a.u., which was 33 times stronger than that of
IgG control. When exosomes, antibodies, or both exosomes and antibodies were absent, the
signals were 44, 17, and 19 a.u., respectively (Figure 4.3F). These studies demonstrated that the
SERS AuNRs and the antibody capture Au slide specifically captured exosomes with targeted
surface proteins and detected them without significant nonspecific interference. The captured
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exosomes with CD63 antibodies were further confirmed using fluorescence imaging with DiO as
the membrane labeling agent (Figure 4.3G). The fluorescence image also shows that exosomes
were distributed evenly on the Au surface. In each experiment, SERS spectra from different
locations in the Au array wells were collected and the averaged spectrum was used for analysis
to account for variation in exosome density at different locations in the well (Figure 4.4)

Figure 4.4. SERS spectra from 5 different locations of the exosome spot. The laser beam is 200
𝜇m in diameter and the exosome spot is 2 mm in diameter. Anti-CD63 antibodies were used as
the targeting ligand to target exosomes derived from MDA-MB-231 cells. 𝜆= 785 nm. Laser
power: 50 mW. Acquisition time: 1s.
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To examine the sensitivity of the assay, we did a titration experiment with a series of
dilutions using CD63 as the capture antibody. Figure 4.5A shows the averaged SERS spectra
(n=3) from exosomes with different concentrations. The dose (exosome concentration)-response
(averaged SERS intensity of the 1497 cm-1 peak with SD from the triplicate experiments) curve
based on data in Figure 4.5A is shown in Figure 4.5B. The studies showed that the limit of
detection (LOD) was 2×106/mL (3.3 fM). The concentration of exosomes in human plasma is
>109/mL.323 Thus, our assay can detect exosomes at a concentration 500 times lower than a
typical concentration of exosomes in plasma. This sensitivity was achieved using a 200 µm
Raman probe (λ = 785 nm) with low laser power (50 mW). The acquisition time for each
spectrum was only 1s. The as-acquired spectrum was baseline-corrected by the EZRaman Reader
V8.1.8 MV signal acquisition software to separate broad emission SERS background. Based on
the exosome volume (15 µL), concentration (2×106/mL), the size of the well (2 mm), and the
size of the laser spot (200 μm), we calculated that the LOD on the Au slide was 300 exosomes.
The SERS signal intensity was linearly proportional to the concentration of exosomes at a range
of 106 to 108 exosome/mL, with a correlation coefficient R2 = 0.97 (Figure 4.5B inset). The
working concentration we used was 6.25 × 107/mL with a working volume of 15 µL. This
sample consumption is comparable to that of the most recent high-sensitivity exosome detection
technique based on plasmon resonance light scattering properties of gold nanoparticles.295
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Figure 4.5. Evaluation of the abilities of the Raman exosome assay for detection and protein
profiling of exosomes. (A) Average SERS spectra (n=3) of exosomes at different concentrations
captured with CD63 antibodies. (B) Dose (exosome concentration)-response (mean SERS signal
intensity of the 1497 cm-1 peak) curve. Linear range is shown in the inset. (C) Average SERS
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To examine the feasibility of the Raman assay for exosome molecular profiling, we
analyzed eight surface proteins from three different categories: epithelial marker EpCAM, breast
cancer markers CD44, HER2, EGFR, IGFR, and exosome markers CD81, CD63, CD9 on the
model MM231 exosomes. Figure 4.5C shows the averaged SERS spectrum for each target
protein (n=3) and Figure 4.5D shows the expression profile of all eight proteins on MM231
exosomes using the data in Figure 4.5C. Isotype IgG was used as the negative control to examine
the nonspecific interactions of the antibodies. The results show that MM231 exosomes have high
expression of CD44 and the three exosome markers CD81, CD63, and CD9. They have very low
expression of EpCAM and the other three breast cancer markers HER2, EGFR, and IGF1R.
These results are consistent with a literature report using a SPR method.292 MM231 cells are
known to overexpress (3+) CD44 with low expression (0-1+) of HER2, EGFR, and EpCAM,324329

which was further confirmed by flow cytometry analysis (Figure 4.5). This suggests that

exosomes reflect the surface marker expressions on their parental cells and thus can be used as a
resource for cancer biomarkers. Our SERS method was further validated using the gold standard
ELISA. ELISA was carried out using the indirect approach, in which exosomes were adsorbed
onto 96-well plates and then labeled with antibodies targeting each protein. The antibodies were
recognized with HRP-conjugated secondary IgG antibody and then detected with the
chromogenic substrate TMB. Figure 4.5E shows the protein profile on MM231 exosomes using
ELISA. Similar to the results with the SERS method, the exosomes have high expression of
CD44, CD81, CD63, and CD9 and low expression of EpCAM, HER2, EGFR, and IGF1R. A
quantitative comparison shows that our Raman assay has a high correlation to ELISA, with a
correlation coefficient R2 of 0.97 (Figure 4.5F).
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Figure 4.6. Flow cytometry analysis of the expression of surface protein markers on cancer
(MM231, MM3688, and SKBR3) and normal (MCF12A) cells. All cells were labeled with PEconjugated antibodies. PE-labeled IgG was used as the control.
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Compared to ELISA, our Raman assay is simpler and faster. With the functionalized Au
chips, the sample preparation only requires exosome capture and labeling, which takes about 1.5
hours. However, ELISA involves a cumbersome procedure including exosome adsorption, plate
blocking, primary antibody binding, secondary antibody binding, and the enzyme-catalyzed
signal production, with a total sample processing time >24 h. In addition, this assay provides
point-of-care use because of the portable nature of the Au chip and Raman spectrometer.

To evaluate whether our method can differentiate exosomes from different cancer cell
lines and differentiate cancer cells from normal cells, we profiled exosomes from two additional
breast cancer cell lines, MM468 and SKBR3, and one normal (immortalized) breast cell line,
MCF12A. Flow cytometry measurements revealed that the surface markers of MM468 cells are
EpCAM (strong), HER2 (moderate), and IGFR (moderate) (Figure 4.6). The surface markers of
SKBR3 cells are EpCAM (strong) and HER2 (strong). Both cell lines have different marker
expression patterns from the MM231 cancer cells. The MCF12A normal cells are EpCAM
positive, but their level is much lower compared to that of MM468 and SKBR3 cells. The size of
exosomes derived from MM468, SKBR3, and MCF12A was 170 ±54, 165 ±38, 156 ±32 nm,
respectively. Figure 4.7 shows a comparison of the protein profiles on exosomes from these
cancer and normal cells. The exosomes exhibited significantly (p < 0.01) different surface
marker profiles across different cell lines. Exosomes from MM468 cells have high expression of
EpCAM and moderate expression of HER2 and IGF1R. Exosomes from SKBR3 cells have high
expression of EpCAM and HER2. As described above, exosomes from MM231 cells have high
expression of CD44 and negligible EpCAM. Exosomes from the MCF12A normal cells have
moderate EpCAM expression.
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Figure 4.7. Protein profiling of exosomes derived from breast cancer cells (MM231, MM468,
and SkBR3) and normal cells (MCF12A). (A-D) Average SERS spectra (n=3) of exosomes
targeting different surface proteins. IgG was used as the control. (E) Comparison of protein
expressions on cancer and normal cells. Data are presented as the mean intensity of the
1497 cm-1 peak with standard deviation (n=3). (F) Colorimetric comparison of protein
expressions on cancer and normal cells based on data in (E). The p-values among the four cell
lines for EpCAM, CD44, HER2, EGFR, IGF1R, CD81, CD63, and CD9 are 1.1×10-6, 5.5×10-8,
1.3×10-14, 4.7×10-3, 1.6×10-6, 1.5×10-8, 2.5×10-7, and 1.7×10-8, respectively.
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Compared to the protein expression on the surface of these cells from flow cytometry analysis, it
is clear that exosomes reflect their originating cells’ surface protein marker expressions,
irrespective of cell lines. Thus, exosomes can be used to identify signature markers for cancer
detection by surface protein profiling. All cell lines are positive for the three exosome markers
CD81, CD63, and CD9.
To evaluate the clinical potential, we used the Raman assay to analyze exosomes in
breast cancer patients. Due to the heterogeneous breast cancer types, we chose HER2-positive
patients (n=10) for a proof-of-concept study. The disease includes invasive lobular carcinoma,
infiltrating ductal carcinoma, and adenocarcinoma of the breast in stages I, II, and III. We
obtained patient plasma samples from the XpressBank at Asterand Bioscience. Although
research has shown that liquid nitrogen-frozen exosomes are stable for over 5 years,330 we used
samples collected within the last three years to ensure high quality. To collect plasma samples
from healthy donors (n =5), we obtained fresh whole blood and extracted exosomes by
differential centrifugation. Using NTA, we determined that exosomes in plasma samples had
mean sizes from 120 nm to 170 nm, with concentrations from 1.0×109/mL to 3×1010/mL (Figure
4.8 and Table 4.1). There were no significant differences in the sizes between cancer patients and
healthy donors. The concentration was heterogeneous in patients and healthy donors. Exosome
concentrations in patient 2 and patient 5 were much higher than those in the other patients.
Exosome concentrations in healthy donors were higher than those in most patients. The
variations in concentration cannot be exclusively ascribed to the age of the samples since all the
healthy samples were freshly collected at the same time and newer than all the patient samples.
Thus, the concentration depends on the individual, irrespective of disease state.
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Figure 4.8 Size distribution of exosomes in human plasma samples from breast cancer patients
and healthy donors characterized with NTA.
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Figure 4.9. Comparisons of surface marker expressions of EpCAM (A, B), CD44 (C, D), and
HER2 (E, F) between cancer patients and healthy donors. (A, C, and E) Averaged SERS spectra
(n=3) from each subject. (B, D, and F) Protein expression profiles based on the SERS data in the
SERS spectra. Data are presented as the mean intensity of the 1497 cm-1 peak with standard
deviation. The p-values between cancer patients and healthy donors for EpCAM, CD44, and
HER2 are 7.4×10-11, 0.097, and <2.2×10-16, respectively.
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Figure 4.10 Comparisons of surface marker expressions of CD81 (A, B), CD63 (C, D), and CD9
(E, F) between cancer patients and healthy donors. (A, C, and E) Averaged SERS spectra (n=3)
from each subject. (B, D, and F) Protein expression profiles based on the SERS data in the SERS
spectra. Data are presented as the mean intensity of the 1497 cm-1 peak with standard deviation.
The p-values between cancer patients and healthy donors for CD81, CD63, and CD9 are 0.037,
0.049, and 0.038, respectively.
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Table 4.1. Characterization of the size and concentration of exosomes in human plasma samples.

III

Size (mean  SD,
nm)
129  29

Concentration
(exosomes/mL)
(4.2  0.5)  109

III

161  43

(1.6  0.1)  1010

III
III

158  44
145  38

(2.0  0.3)  109
(1.9  0.2)  109

III

137  42

(1.3  0.1)  1010

III

144  33

(2.2  0.2)  109

I

151  38

(1.4  0.1)  109

I

148  37

(1.1  0.1)  109

II
II

168  36
154  35

(2.1  0.2)  109
(1.2  0.1)  109

-

157  34
152  33
133  25
169  37
161  32

(9.0  0.3)  109
(7.5  0.6)  109
(1.8  0.2)  109
(8.8  0.5)  109
(7.6  0.2)  109

Sample ID Clinical diagnosis

Stage

Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10
Healthy 1
Healthy 2
Healthy 3
Healthy 4
Healthy 5

Invasive lobular
carcinoma
Infiltrating ductal
carcinoma
Adenocarcinoma
Invasive lobular
carcinoma
Invasive lobular
carcinoma
Invasive lobular
carcinoma
Infiltrating duct
carcinoma
Infiltrating ductal
carcinoma
Adenocarcinoma
Infiltrating ductal
carcinoma
-

Based on our in vitro studies, EpCAM, CD44, and HER2 are biomarkers to distinguish
breast cancer exosomes from normal cell-derived exosomes. Thus, we chose these three markers
to analyze exosomes from the plasma samples (Figure 4.9), together with the three exosome
markers CD81, CD63, and CD9 (Figure 4.10). The levels of EpCAM and HER2 were
significantly higher in the tested breast cancer patient samples than in the control groups (p <
0.01 for both markers). The levels of CD44 (p = 0.097), CD81 (p = 0.037), CD63 (p = 0.049),
and CD9 (p = 0.038) were not significantly different in the patient samples than in the controls.
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Figure 4.11. Receiver operation characteristic (ROC) curves generated based on patient profiling
data in Figure 4.9

Our finding of HER2 marker (AUC = 1 from ROC curve, Figure 4.11) on exosomes in the
HER2-positive breast cancer patient is consistent with previous studies with a SPR method. 293 In
addition, we identified EpCAM as another biomarker to differentiate exosomes from breast
cancer patients from normal controls (AUC = 1, Figure 4.11) EpCAM has been previously
identified as an exosome-based biomarker for ovarian cancer in ascites samples.280 Here we
report EpCAM as an exosome-based biomarker for breast cancer. The early promise of these
proteins for breast cancer diagnosis, however, requires further validation with larger cohorts.
4.4. Conclusion
In conclusion, we have developed a simple, rapid, inexpensive, highly sensitive, and
highly specific Raman-based assay for point-of-care detection and molecular profiling of
exosomes. Using the assay and model exosomes from breast cancer cells, we showed that
exosomes reflect their donor cancer cells’ surface biomarker expressions, suggesting the
potential of exosomes as biomarkers for cancer detection and investigation. Our assay can be
100

used to differentiate different subtypes of cancer cells and differentiate cancer cells from normal
cells. Using the assay, we have identified HER2 and EpCAM biomarkers on exosomes for
diagnosis of HER2-positive breast cancer patients. The assay can be widely used for basic and
clinical cancer research. Using the classic high speed and high throughput micro drop printing
technology, the assay can be readily translated into a microarray platform, offering throughput
close to 1,000 test sites on a single Au chip. In addition, the microdrop printing technology can
automate the sample processing steps, dramatically enhancing the efficiencies of exosome
molecular analysis. This next- generation Raman exosome assay has the potential to
revolutionize exosome research and realize a novel cancer liquid biopsy approach for cancer
research and early detection. We would like to point out that our method is a detection method
that requires initial exosome isolation.
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Chapter 5: Conclusion and Further Perspectives
In this dissertation, we have reported in chapter three, the experimental and
computational studies on the facile synthesis and characterization of multifunctional iron oxidegold core shell nanoparticles in sphere, popcorn and star shapes. These nanomaterials can be
finely tuned in shell thickness, shape and size from 70 to 200 nm (Figure 3.7). These
nanoparticles were made using seed-mediated growth method in which newly formed gold atom
were added onto the gold-seeded iron oxide octahedrons to form gold shell. We found that by
controlling the amount of additive such as silver nitrate and the reducing agent, ascorbic acid, in
the growth solution result in an evolution of the shell into different shapes (Schematic 3.1).
Using discrete dipole approximation calculation and experimental results, we showed that
nanostars and nanopopcorns exhibited redshifted plasmon resonance compared with the
nanospheres (Figure 3.11). With a dramatic increase of interest in the optical properties and
applications of multifunctional nanomaterials, this study will have an importance across many
fields including biomedical and material research. Even though this study has provided an
indispensable insight into the synthesis and growth process of anisotropic nanoparticles, we
found that the correlation between the DDA calculated and experimental NST spectra does not
correlate well as for NSP and NPC spectra (Figure 3.12). This is possibly caused by the number
and length of the tip on the NSTs. Therefore, it is crucial to have an extensive study that
investigates the exact correlation between LSPR peaks and NST properties of tip length, width as
well as the number of the tips. Another crucial challenge is achieving a homogenous
monodispersity, controlled size and shape reproducibility and the ability to scale up the
synthesized nanoparticles. It Should also be worthwhile to mention that the cost of fabricating
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these nanomaterials in higher quantity is higher than conventional bulk material synthesis hence,
being out of reach to many people who can’t afford it.
In chapter four, we have demonstrated that with the combination of surface enhanced
raman scattering of multifunctional nanorods and a portable Raman exosome assay, for cancer
derived exosome diagnostics. As the early detection of cancer concept keeps dominating the
academic research industry for many years now, the world is still racing to achieve cost-efficient,
user friendly personalized-point of care cancer detection assays that are very sensitive,
reproducible, fast and portable accessible by everyone but most of all, capable of identifying new
cancer markers that are specific for early cancer diagnosis. To achieve this, a large number of
patients of different cancer types and from early cancer stage to late stage numbers need to be
studied carefully. As we have shown, we are able to detect and profile exosomes from both
plasma fluid and cancer cell with the limit of detection of 2×106 exosomes/mL and analyze over
80 purified samples on a single device within two hours (Figure 3.1A). Using the assay, we were
able to identify HER2 and EpCAM biomarkers on exosomes from HER2-positive breast cancer
patients’ plasma with HER2 and EpCAM exhibiting significantly higher expression
(p = 2.2×10-16 and p = 7.4×10-11) respectively than exosome derived from healthy donors (Figure
4.9). This suggests that the diagnostic potential of these markers could pave a way to the
development of blood-based cancer liquid biopsy for cancer detection, diagnostics and
monitoring. The future work on this study should focus on the automation of both the sample
process and data analysis; this can avoid any human error and would enhance the efficiency of
exosome molecular analysis. Finally, by combining the high speed and high throughput
microdrop printing technology, this assay can readily be translated into a microarray platform
which would offer more than 1000 test sites on a single Au chip. Even though, there is an urgent
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need to perfect the existing techniques for the cancer biomarker measurement while creating new
detection tools; there is still a void of building instruments that are able to detect traces of cancer
marker at a clinical level as most of the current techniques still struggle with sensitivity and
selectivity issues especially since the naturally occurring cancer markers are found in a very
small concentration. Therefore, the complex environment and low concentration of exosomal
marker can be overcome by single exosome detection which would probe single cancer derived
exosome. This would provide an enormous information which can also be quantified to provide
information on numbers of markers per cancer derived exosome, the number of cancer positive
exosome in a given blood sample as well as how many exosomes in a sample that are expressing
the target marker. This information will revolutionize the cancer therapy as it is very useful for
clinical monitoring of cancer and patient treatment. The future work will also focus on the way
to minimize the time it takes to run the sample and obtain results. This will make these tools
clinically capable of being used in medical setting.
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